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Abstract
Bempedoic acid (BA) is a novel LDL cholesterol-lowering compound. Preclinical studies
revealed that BA inhibits hepatic cholesterol and fatty acid synthesis through inhibition of
ATP-citrate lyase and activation of AMP-kinase. In the current study we tested the ability of
BA to prevent diet-induced metabolic dysregulation, inflammation and atherosclerosis in
Ldlr-/- mice fed a high-fat high-cholesterol diet (HFHC). BA supplementation to the HFHC
diet at 3, 10 or 30 mg/kg/d significantly attenuated diet-induced hypercholesterolemia,
hypertriglyceridemia, hyperglycemia, hyperinsulinemia, fatty liver and obesity over the 12week study compared to HFHC alone. Livers of BA-treated mice displayed decreased fatty
acid synthesis, and increased β-oxidation, AMP-kinase activation, and peroxisome
proliferation. BA reduced hepatic and aortic inflammatory gene expression and MAPK
signaling, aortic esterified cholesteryl, and atherosclerotic lesion development. This
demonstrates that BA effectively improves hepatic lipid metabolism and reduces plasma and
tissue lipids, markers of inflammation, and atherosclerosis in a mouse model of metabolic
dysregulation.
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Chapter 1

1

Review of thesis topics
1.1

General Introduction

Cardiovascular disease (CVD) continues to be a leading cause of death in developed
countries, exacerbated in part by the increasing prevalence of Type 2 Diabetes and the
metabolic syndrome (1, 2). The rates of CVD mortality have been declining over the
previous decades due to significant advancements in our understanding of its
pathophysiology and therapies for risk management (3, 4). Underlying the progression of
CVD is atherosclerosis, a chronic inflammatory condition, which can develop silently for
decades and not be identified until after a major cardiovascular event has occurred, such
as myocardial infarction, stroke, or peripheral artery disease (1, 5).

1.2

Cardiovascular Disease and Dyslipidemia

It has been known for some time now that cholesterol plays a major role in the
development of CVD and over the past century there have been huge advancements in
our understanding of this relationship (4). However, in addition to its role in CVD
progression it is important for many other bodily functions, both as a structural and
signaling molecule. Cholesterol is required for the synthesis of steroid hormones, bile
acid, fat soluble vitamins and myelin sheath while also serving as a major structural
component of cell membranes (6, 7).
Cholesterol traveling within the circulation is packaged into small micelle particles
known as lipoproteins (further characterized in section 1.2.2). Low- and high-density
lipoproteins (LDL and HDL, respectively) are two of the classes of lipoproteins by which
cholesterol is transported within the circulation. Plasma LDL cholesterol (LDL-C) or
non-HDL cholesterol (HDL-C) have been established for some time as major risk factors
for CVD (8, 9). For example, evidence from randomized clinical trials examining statin
efficacy have demonstrated that for every 1 mmol/L lowering in LDL-C, there was a 22%
reduction in major vascular events and a 10% reduction in all-cause mortality (10). An
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LDL-C concentration >5.0 mmol/L would be considered severe dyslipidemia likely due
to a genetic disorder and warrant pharmacological treatment (11, 12). HDL-C has long
been thought to be cardioprotective but more recently, multiple therapies that
pharmacologically raise HDL have so far failed to demonstrate therapeutic benefit (13).
Clinicians will typically measure plasma LDL-C and HDL-C concentrations both to
estimate CVD risk and to gauge efficacy of treatment.
Dyslipidemia consists of elevated plasma LDL-C (hypercholesterolemia) and TG
(hypertriglyceridemia) and low HDL-C and thus increases the risk of developing CVD. It
can either be of genetic origin or secondary to other factors such as age, obesity, diabetes,
and metabolic syndrome (14, 15). This lipid profile often seen in diabetics is referred to
as diabetic dyslipidemia which, at least in part explains why patients with diabetes are at
a much greater risk for developing CVD (16, 17).
The high incidence of CVD is linked to, and likely driven by the increasing prevalence of
so-called “diseases of affluence” such as insulin resistance (leading to Type 2 Diabetes),
obesity, and hepatic steatosis, all of which play a role in the development of atherogenic
dyslipidemia and CVD (18–20). This cluster of risk factors, along with high blood
pressure, have become known as the metabolic syndrome (15, 21). The patient population
represented by this clustering of cardiometabolic abnormalities has been increasing in
prevalence for some time, and will likely continue to do so thereby representing a
significant challenge when it comes to managing the worldwide CVD burden (22).
Altogether, there is a growing need for therapies that will further lower LDL (or nonHDL) cholesterol while also treating other risk factors associated with the metabolic
syndrome. The standard of care used clinically has improved tremendously over the years
and there are several experimental therapies with significant therapeutic potential in late
stage clinical development (reviewed in section 1.7). However, in order to counter the
increasing CVD prevalence, there is a need for a better understanding of the molecular
pathways that govern disease progression in order to identify novel therapeutic targets.
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1.2.1

Atherogenesis

Vessels that are most susceptible to atherosclerosis are the medium and large sized
arteries. The structure of a normal artery is shown in Figure 1-1. On the most basic level,
it consists of an outermost, collagen-rich layer (adventitia), followed by an elastic middle
layer (media), then a thin innermost layer (intima) facing the vessel lumen and exposed to
continuous blood flow (Figure 1-1). Additionally, the medial layer is lined externally and
internally by the external and internal elastic membranes, respectively (23). Each layer is
defined by their cell types and macromolecule extracellular matrix composition. The
intima is a thin layer of endothelial cells surrounded by a subendothelial space comprised
of extracellular matrix proteins such as collagen and elastin. Humans and other larger
mammals also contain smooth muscle cells (SMCs) within the intima in contrast to
model organisms such as rodents, which do not (23, 24). The internal elastic membrane
marks the start of the media. This thick elastin-rich layer made up of many SMCs and
extends until the external elastic membrane (25). Lastly, the adventitial layer contains a
heterogeneous combination of cells including vascular progenitor cells, fibroblasts and
resident arterial macrophages. High collagen content within the adventitia provides
tensile strength to the arteries (25–27).
The initiation of atherogenesis begins when apolipoprotein (apo) B-containing
lipoproteins circulating in the blood enter the arterial intima (Figure 1-2A). This occurs
predominantly in arteries experiencing oscillatory, non-uniform, and lower velocity flow
(28). While in the subendothelial space lipoproteins will interact with the extracellular
matrix leading to their retention and modification. Oxidative modification by reactive
oxygen species (ROS) or lipoxygenases of lipids and LDL (oxLDL) elicits immune
responses and complex interactions with and between the endothelial cells, SMCs, and
immune cells (29, 30). Endothelial cells will express adhesion molecules and secrete
chemokines resulting in the recruitment of leukocytes (mostly monocytes) to the area of
lipid deposition. Within the arterial intima, monocytes will differentiate into macrophage
and phagocytose (engulf) accumulated oxLDL particles, generating lipid-loaded foam
cells (31) (Figure 1-2A). Lipid deposition within the intima, referred to as fatty streaks,
accumulates over time resulting in the thickening of the intimal space forming a growing
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atherosclerotic plaque (Figure 1-2B). Plaque development continues with the infiltration
and proliferation of SMCs from the media and monocytes from the circulation (Figure 12C). Cellular apoptosis and the accumulation of debris and cholesterol crystals lead to the
formation of a necrotic core. SMCs secrete collagen to generate a fibrous cap overlaying
the growing plaque and conferring stability (31–33) (Figure 1-2D). Several factors can
lead to the destabilization, erosion and potential rupture of the plaque fibrous cap,
including a growing necrotic core, collagen degradation by enzymes such as matrix
metalloproteases (MMPs), along with plaque neovascularization, microcalcification and
remodeling (32–36). Plaque rupture exposes the highly thrombotic necrotic core to the
blood (Figure 1-2E). Clinically, this can lead to the sudden onset of major vascular events
as the thrombi can occlude the lumen or break off from the plaque and occlude distal
arteries in locations such as the heart or brain, presenting clinically as a myocardial
infarct or stroke, respectively (5, 29, 36).
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Figure 1-1 Vessel structure and cell types
A blood vessel consists of three main layers: the outermost, collagen-rich layer
(adventitia), the elastic middle layer (media), and the thin, innermost layer (intima) facing
the vessel lumen. Each of these layers are separated by elastic membranes and are further
characterized by unique cell types (21-25).
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Figure 1-2 Atherogenesis
The development of atherosclerosis occurs over several decades, beginning early in life
when lipoproteins circulating in the blood enter the arterial intima. Once here, monocytes
will differentiate into macrophage and phagocytose accumulated oxidized LDL particles,
generating foam cells (A). Continued lipid deposition within the intima generates fatty
streaks, resulting in the thickening of the intimal space forming a growing atherosclerotic
plaque (B). Plaque development continues with the infiltration and proliferation of
smooth muscle cells from the media which begin to secrete collagen to stabilize the
growing plaque (C). Cellular apoptosis and the accumulation of debris and cholesterol
crystals lead to the formation of a necrotic core (C). Continued secretion of collagen
generates a fibrous cap overlaying the growing plaque and conferring stability, while the
necrotic core can continue to grow (D). Thinning of the fibrous cap causes destabilization
of the plaque and increases its susceptibility to rupture. Plaque rupture exposes the highly
thrombotic necrotic core to the blood (E). Thrombi formation can occlude blood vessels
and rapidly lead to serious clinical events (26-34).
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1.2.2

Lipoproteins

In addition to cholesterol, lipoproteins contain triacylglycerol, phospholipids and
proteins, the ratios of which determine the density and thus classification of the
lipoprotein. They are spherical particles with an outer hydrophilic monolayer of free
cholesterol, phospholipids, and apolipoproteins surrounding a hydrophobic core of
triacylglycerol (TG) and cholesteryl ester (CE). Lipoprotein solubility allows for the
transportation of insoluble hydrophobic lipids within the circulation throughout the body
(37).
In addition to different lipid composition, lipoprotein classes also differ in terms of size,
density, and the types of apolipoproteins with which they associate. The largest, lowest
density class of lipoproteins are chylomicrons which originate from the intestine and
contain predominantly dietary TG with a small amount of CE derived from the diet or
reabsorbed biliary cholesterol. Very low-density lipoproteins (VLDL) are synthesized by
the liver and its core contains primarily TG plus a greater amount of CE content than
chylomicrons. Hydrolysis of chylomicron and VLDL TG result in smaller, denser
particles referred to as chylomicron remnants and intermediate-density lipoproteins
(IDL), respectively. Collectively, chylomicrons and their remnants, IDL, and VLDL all
contain apoB and are referred to as triglyceride-rich lipoproteins (TRLs). Further removal
of IDL-TG by hepatic lipase leads to the formation of LDL, which contains a relatively
high CE content. Lastly, high-density lipoproteins (HDL) also contains a high CE content
but serve a unique function known as reverse cholesterol transport, which delivers
cholesterol from peripheral tissues back to the liver for potential excretion as bile (37,
38). Further characterization of the classes of lipoproteins in terms of composition,
origin, associated apolipoproteins, and function are described in Table 1-1 and their
metabolism is summarized in section 1.3.
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Table 1-1 Lipoprotein classification
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1.3

Lipoprotein Metabolism

Lipoproteins can either be formed from exogenous dietary lipids in intestinal cells
(enterocytes), or from de novo synthesis in liver cells (hepatocytes).

1.3.1

Enteric lipoprotein production from exogenous lipids

Dietary lipids are readily absorbed by small intestine enterocytes for packaging into
chylomicrons for transport throughout the body. In the gut, dietary TG is hydrolyzed by
pancreatic lipases to free fatty acids and monoacylglycerol while CE is hydrolyzed to a
free cholesterol and free fatty acid (39). Following entry into the enterocyte via active
and passive transporters, these lipids are re-esterified into TG and CE to be packaged into
chylomicrons. Microsomal triglyceride transport protein (MTP) facilitates chylomicron
formation by loading lipids onto the scaffolding protein apoB48. The fully-formed, TGrich chylomicron is secreted from the enterocyte into the lymphatics, eventually entering
the bloodstream. Within the lymphatics and circulation, chylomicrons become enriched
with apolipoproteins E and C. Now the fully-formed chylomicron particle contains
apolipoproteins B48, CI, CII, CIII, and E and will circulate to peripheral tissues for
further metabolism (section 1.3.3) (39–42).

1.3.2

Hepatic lipoprotein production

The liver acts as a central mediator of lipid homeostasis by controlling the production of
lipoproteins to be secreted for use by the rest of the body. This involves the formation of
apoB100 containing particles known as VLDL. TG for export are synthesized from free
fatty acids derived from either chylomicrons, adipose tissue TG, or from de novo
synthesis (lipogenesis). Cholesterol to be exported can be chylomicron-derived from the
exogenous pathway but the majority of cholesterol in the body is synthesized de novo by
the liver (reviewed in section 1.4).
Similar to apoB48 and chylomicrons, apoB100 serves as the scaffold for hepatic VLDL
synthesis. Newly synthesized apoB100 peptides are rapidly degraded if there is low TG
availability. When TG is available, apoB100 is co-translationally lipidated with TG, CE,
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and phospholipids by MTP in the endoplasmic reticulum (ER) lumen. The newly
assembled VLDL particle can now be secreted from the hepatocyte. Constant synthesis
and degradation of apoB peptides in enterocytes and hepatocytes allows for the rapid
export of lipoprotein particles when there is a sudden influx of intracellular TG (43).
HDL production occurs in the circulation after the hepatic synthesis and secretion of
apoAI. Free apoAI binds to ATP-binding cassette (ABC)-A1 (ABCA1) on the surface of
peripheral tissues which facilitates the loading of phospholipid and free cholesterol. This
generates a discoidal particle known as pre-β HDL, which can undergo further lipidation
by ABCG1 and cholesterol esterification by lethicin-cholesterol acyltransferase (LCAT)
generating more mature, spherical HDL particles (44, 45).

1.3.3

Metabolism of circulating lipoproteins

As chylomicrons and VLDL travel through the circulation, lipoprotein lipase (LPL)
hydrolyses the lipoprotein TG. LPL resides on the luminal surface of endothelial cells
lining capillaries that perfuse adipose, cardiac, and skeletal muscle tissue. Released free
fatty acids are taken up by the peripheral tissues, a processes requiring apoCII as an LPL
cofactor. As already mentioned, hydrolysis of the core TG within chylomicrons and
VLDL results in the formation of a smaller and denser particle referred to as chylomicron
remnants and IDL, respectively. IDL can be further metabolized by hepatic lipase to form
CE-rich LDL. These lipoproteins remain in the circulation until being cleared by
endocytosis at the liver and peripheral tissues. LDL is cleared by the LDL receptor
(LDLR) using apoB as the receptor ligand while IDL is cleared by LDLR-related proteins
using apoE as the receptor ligand (37, 38, 42, 46).
Circulating HDL has two ways of delivering cholesterol back to the liver for reverse
cholesterol transport. First, hepatic scavenger receptor B1 (SRB1) binds to and removes
CE from HDL particles. Otherwise, cholesterol ester transfer protein (CETP) mediates a
lipid exchange between HDL and TRLs. Specifically, CE from HDL is exchanged for TG
from TRLs. This results in CE-rich apoB-containing lipoproteins (such as chylomicron
remnants, IDL and LDL) which can subsequently be taken up by the liver. HDL gains
TG from the TRLs which can be hydrolyzed by hepatic lipase. TG-rich HDL has reduced
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affinity for apoA1 favoring their dissociation. The lipid-poor apoA1 can now be lipidated
again by ABCA1 to form new HDL, creating a cycle of HDL-CE transport from
peripheral tissues to the liver (13, 37, 38).

1.4

Hepatic Fatty Acid and Cholesterol Metabolism

Hepatic de novo lipogenesis of cholesterol and TG both use cytosolic acetyl-CoA as their
initial substrate. Acetyl-CoA is not only a substrate for several anabolic processes, it can
be derived from a variety of catabolic ones such as glycolysis and fatty acid β-oxidation
(47). From acetyl-CoA the lipogenesis pathways diverge and acetyl-CoA enters either the
cholesterol or fatty acid biosynthetic pathways.

1.4.1

Cholesterol synthesis

The cholesterol biosynthetic pathway begins with the formation of acetoacetyl-CoA from
two acetyl-CoA molecules followed by the addition of another acetyl-CoA molecule to
create 3-hydroxy-3-methylglutarate-CoA (HMG-CoA). The next step has a clinical
significance that is difficult to overstate. The conversion of HMG-CoA to mevalonate by
HMG-CoA reductase (HMGCR) represents both the rate-limiting and first committed
step of cholesterol and isoprenoid biosynthesis. This made way for the discovery of
HMGCR inhibitors, known as statins that are in widespread clinical use today (reviewed
in section 1.7.1). Mevalonate is converted into isoprene units which are subsequently
polymerized into a 30-carbon long squalene chain. Finally, squalene is cyclized followed
by additional modifications to yield a 27-carbon cholesterol molecule (48, 49).

1.4.2

Fatty acid synthesis

Fatty acid synthesis by de novo lipogenesis also begins with acetyl-CoA which is
carboxylated by acetyl-CoA carboxylase (ACC) to form malonyl-CoA. The fatty acid
synthase (FAS) complex adds additional units of acetyl-CoA to malonyl-CoA to generate
an acyl-CoA. With subsequent additions of acetyl-CoA, FAS generates the 16-carbon
acyl-CoA known as palmitic acid. Palmitic acid can undergo unsaturation or further
elongation followed by esterification with glycerol to form monoacylglycerol. The
further esterification of one or two more fatty acids results in the formation of
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diacylglycerol and triacylglycerol, respectively. Triacylglycerol, or TG is the primary
means of fatty acid storage and transport, as the hepatocyte can store them in lipid
droplets or export them as VLDL (2, 50, 51).

1.4.3

Sterol response element-binding proteins

Another important layer in the regulation of lipid synthesis is the sterol response elementbinding protein (SREBP) pathway. SREBP is a transcription factor encoded by two
genes, SREBP1 and SREBP2. The former generates two isoforms due to alternative
splicing, SREBP-1a and SREBP-1c. Generally, the active SREBP-1c protein regulates
genes involved in the synthesis of fatty acids while SREBP-2 deals more so with
cholesterol synthesis gene expression and SREBP-1a regulates both (52).
SREBPs are translated into their full length, endoplasmic reticulum-bound precursor
form where they remain in proximity to the SREBP-cleavage activating protein (SCAP)
and are held in place by the insulin-induced gene (Insig). When intracellular sterols are
low or depleted, Insig releases SCAP which translocates the membrane-bound SREBP to
the Golgi apparatus. Here proteolytic processing releases the SREBP protein from the
Golgi membrane in its active form. It can now translocate to the nucleus where it
promotes lipogenic gene expression by recognizing sterol receptor elements (SREs)
within the promotors of target genes. Additionally, active SREBPs can further upregulate
their own gene expression due to SREs located within their own promoter regions (52,
53).

1.4.4

Fatty acid oxidation

Hepatocytes process intracellular free fatty acids by both esterification into TG
(described above) and also through fatty acid β-oxidation. In a process similar to the
reverse of fatty acid synthesis, β-oxidation breaks down free fatty acids in cycles, where
the fatty acid is shortened by one acetyl-CoA unit at a time. This acetyl-CoA can then be
fully broken down to carbon dioxide and water in the tricarboxylic acid cycle or
condensed into ketone bodies and secreted into the circulation (54).
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To protect cells against fatty acid-induced lipotoxicity (see section 1.6.3.1), fatty acid βoxidation is tightly-regulated in conjunction with esterification into TG for either storage
or export as VLDL. β-oxidation can only occur inside the mitochondria matrix and while
short and medium chain fatty acids can freely diffuse through the mitochondrial
membrane, long-chain fatty acids (such as palmitoyl-CoA) cannot. Instead, carnitine
palmitoyl transferase (CPT)-1α must first convert the long-chain acyl-CoA to an acylcarnitine to allow for transfer across the mitochondria membrane. Once inside the
mitochondria matrix CPT2 converts the acyl-carnitine back into a long-chain acyl-CoA,
which can now undergo β-oxidation (16, 55).
The rates of de novo fatty acid synthesis and fatty acid β-oxidation are coordinated in
such a way as to prevent futile cycling where a free fatty acid is broken down into acetylCoA subunits just to be re-synthesized back into a free fatty acid. This regulation is
mediated by malonyl-CoA, the product of ACC from the first step of fatty acid synthesis
(section 1.4.2). CPT1α is inhibited by malonyl-CoA, thus suppressing β-oxidation by
preventing long-chain acyl-CoA from entering the mitochondria matrix (54, 56). This
coordination between the rates of fatty acid synthesis and β-oxidation is important for
proper regulation of energy flux, in instances such as transitioning from fasting to
feeding.
In addition to the mitochondria, peroxisomes are a second site of β-oxidation. Very longchain fatty acids, typically greater than 20 carbons, must be metabolized by peroxisomal
β-oxidation. This process generates a shorter acyl-CoA which can subsequently undergo
mitochondrial β-oxidation. Acyl-CoA oxidase (ACO) is the rate-limiting enzyme in
peroxisomal β-oxidation and ACO deficiency results in the accumulation of very long
chain fatty acids (57–59).

1.5

Hepatic Insulin Signaling

Insulin is a peptide hormone essential for driving the body’s metabolic response
following the ingestion of a meal. It is secreted by pancreatic β-cells into the circulation
after feeding and signals to peripheral insulin-sensitive tissues such as adipose, liver, and
muscle. Insulin signaling is initiated when insulin binds to and activates the insulin
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receptor (IR) activating its tyrosine kinase and promoting phosphorylation of the insulin
receptor substrate (IRS). This allows for docking of proteins containing Src homology 2
(SH2) domains such as phosphoinositol 3-kinase (PI3K) which becomes active. PI3K
activates phosphoinositide-dependent kinase 1 (PDK1) which phosphorylates and
activates Protein Kinase B (AKT), a central mediator of the metabolic effects of insulin.
Active AKT phosphorylates different targets relating to glucose and lipid metabolism
(Figure 1-3, sections 1.5.1, 1.5.2) (50, 60, 61).

1.5.1

Regulation of glucose metabolism

The primary function of insulin on the liver is to suppress hepatic gluconeogenesis during
the fed state. Active AKT phosphorylates and inhibits the transcription factor forkhead
box-O1 (FOXO1) resulting in its exclusion from the nucleus. This prevents FOXO1mediated transcription of gluconeogenic genes such as glucose 6-phosphatase (G6P) and
phosphoenolpyruvate carboxykinase (PEPCK) (Figure 1-3). However, this model does
not explain how insulin can acutely regulate gluconeogenesis since it has been known for
some time that insulin rapidly suppresses hepatic glucose output well before any changes
in both G6P or PEPCK protein expression are observed (60). Very recent evidence
suggests that this could be explained by effects of insulin outside the liver. An additional
function of insulin is to inhibit adipose tissue lipolysis, thus reducing the flux of free fatty
acids and glycerol to the liver. Perry, et al. (62) demonstrate that adipose tissue-derived
acetyl-CoA (from free fatty acid β-oxidation) and glycerol serve as the primary
gluconeogenic substrates used by the liver. Thus, in response to insulin administration,
rapid inhibition of adipose tissue lipolysis was responsible for the acute suppression of
hepatic glucose production. More simply put, insulin acutely suppresses hepatic
gluconeogenesis through an extra-hepatic mechanism.
Another function of hepatic insulin signaling relating to glucose metabolism is the
stimulation of glycogen synthesis. AKT phosphorylates and inhibits glycogen synthase
kinase-3 (GSK3), which is an inhibitor of glycogen synthase (GS). Therefore, GS is
active and under fed conditions will convert glucose into glycogen for storage (63)
(Figure 1-3).
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Figure 1-3 Hepatic insulin signaling
Insulin binds to the insulin receptor (IR) leading to activation of insulin receptor
substrates (IRS) by tyrosine phosphorylation (pY). This leads to activation of
phosphoinositol 3-kinase (PI3K) which recruits Protein Kinase B (AKT) inducing its
serine (pS) and threonine (pT) phosphorylation by phosphoinositide-dependent kinase 1
(PDK1). Active AKT phosphorylates several targets which regulate glucose and lipid
metabolism. Forkhead Box-O1 (FOXO1) phosphorylation results in its nuclear exclusion
preventing it from upregulating gluconeogenic gene expression. Proline-rich AKT
substrate of 40 kDa (PRAS40) and tuberous sclerosis complex 2 (TSC2) phosphorylation
blocks inhibition of mammalian target of rapamycin complex 1 (mTORC1) which can
activate the lipogenic transcription factor sterol regulatory element binding protein-1c
(SREBP1c). Additionally, AKT also promotes glycogen synthesis by phosphorylating
and inhibiting glycogen synthase kinase-3 (GSK3), which is an inhibitor of glycogen
synthase (GS).
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1.5.2

Regulation of lipid metabolism

Hepatic insulin signaling also triggers de novo lipogenesis (section 1.4) through the
P13K-AKT pathway, especially during periods of excess nutrient availability. When
AKT is phosphorylated and activated by insulin it phosphorylates a number of targets
ultimately leading to increased activity of the lipogenic transcription factor SREBP-1c
(64). Insulin increases SREBP-1c expression through the activation of the mammalian
target of rapamycin complex (mTORC)-1. This is done by AKT phosphorylating and
inhibiting two upstream inhibitors of mTORC1, proline-rich AKT substrate of 40 kDa
(PRAS40) and tuberous sclerosis complex 2 (TSC2) (Figure 1-3) (64).
Additionally, insulin inhibits lipoprotein secretion, even while stimulating de novo
lipogenesis via inhibition of FOXO1. Besides promoting gluconeogenic gene expression,
FOXO1 also promotes the transcription of MTTP and APOC3. The MTP protein
(described in sections 1.3.2 and 1.3.3) is responsible for the assembly of lipoproteins by
loading TG onto apoB. Reducing MTP expression thus limits lipoprotein synthesis and
secretion. ApoCIII is thought to play a role in subsequent lipoprotein synthesis and
secretion, so limiting its expression can further inhibit lipoprotein production (65, 66).

1.5.3

Insulin resistance and Type 2 Diabetes

Insulin resistance is one of the components of the metabolic syndrome and it describes
the state where tissues fail to appropriately respond to insulin. The pancreas compensates
for this by increasing insulin production, creating a state known as hyperinsulinemia.
With time this can develop into Type 2 Diabetes. The body now cannot regulate glucose
homeostasis due to an inability to synthesize insulin. Extreme hyperglycemia ensues
which is life-threatening and must be managed with exogenous insulin injections (67).
The result of insulin resistance with hyperinsulinemia depend on the organ system
effected. In adipose tissue, insulin fails to suppress TG lipolysis, thus increasing
circulating free fatty acids. In muscle, insulin fails to upregulate glucose transporter type
4 (GLUT4) translocation to the cell membrane limiting muscle glucose uptake resulting
in hyperglycemia. Most notably, in liver insulin fails to suppress gluconeogenesis while
continuing to stimulate lipogenesis, creating the phenotype seen in patients with diabetes
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of hyperinsulinemia, hyperglycemia, and hyperlipidemia (68). This paradoxical effect
was suggested to be due to a bifurcation in the insulin signaling pathway, where AKT
fails to inhibit FOXO1 and gluconeogenic gene expression while continuing to stimulate
the mTORC1-SREBP1c lipogenic pathway (69–72). However, insulin resistance is
typically thought to occur by serine phosphorylation of IRS1, an inhibitory event which
dampens insulin signaling through the PI3K-AKT pathway, which should in theory effect
all targets of AKT, not just FOXO1. Insulin resistance characterized by IRS-1 serine
phosphorylation occurs via multiple mechanisms such as MAPK signaling (a negative
feedback effect of insulin signaling) and protein kinase C-ε (PKCε) activation by
lipotoxic intermediates such as diacylglycerol (DAG) (2, 50, 67, 73). More recent
evidence suggests that the observed stimulation of both gluconeogenesis and lipogenesis
despite reduced insulin sensitivity may be a result of increased nutrient flux to the liver,
as is seen with insulin resistance (60, 62, 74, 75). Indeed, the increased adipose tissuederived free fatty acid flux to the liver seen in insulin resistance has been shown to be the
major driver of hepatic TG synthesis (75) and glucose production (62) independent of
insulin signaling.

1.6

Hepatic Steatosis and Inflammation

Tightly linked to conditions such as insulin resistance, obesity, and dyslipidemia is the
process of hepatic steatosis, or the accumulation of fat in the liver. Also factoring into
these metabolic conditions and CVD risk factors is inflammation, although the role this
plays is much more difficult to define.

1.6.1

Normal liver biology and morphology

The liver is responsible for many functions vital for survival. In addition to regulating
glucose, lipid, and lipoprotein metabolism (discussed in previous sections), other
functions involve synthesis (bile acids, albumen, clotting factors, hormones, other
proteins), storage (glycogen, vitamins), and metabolism (prodrugs, toxins, ammonia,
bilirubin). While not fully comprehensive, this list does demonstrate some of the
functions that the liver is involved in such as digestion, oncotic pressure maintenance,
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clotting, nutrient storage, drug metabolism, detoxification, the urea cycle, and the
removal of other waste (76, 77).
So far, when referring to the liver it is usually the hepatocyte being described.
Hepatocytes make up approximately 80% of the liver by mass and are responsible for
most functions attributed to the liver. However, the liver has a very complex
morphological structure which contains several additional cell types organized into
lobules (Figure 1-4). The hepatic artery and portal vein deliver blood from the arteries
and intestine, respectively. These arrange alongside bile ducts forming what are called
portal triads. Blood flow from both the hepatic artery and portal vein enters the region
known as the sinusoid, which drains to the central vein and exits the liver. Liver lobules
are organized in hexagonal structure with six portal triads surrounding a central vein
(Figure 1-4).
The lobule structure seen in the liver consists of several cell types in addition to
hepatocytes, shown in Figure 1-4. First, sinusoid endothelial cells make up the lining of
the vasculature, separating hepatocytes from the sinusoid, where blood flow occurs (78).
The resulting area between the hepatocytes and sinusoid endothelial cells is referred to as
the space of Disse. Cholangiocytes are biliary epithelial cells lining the bile ducts into
where hepatocytes secrete bile acid and cholesterol for digestion by facilitating micelle
formation and lipid absorption (79). Kupffer cells (or Ido cells) are liver-specific
macrophage thought to originate from circulating monocytes and thus are for host
immune defense (80). Hepatic stellate cells are important for the storage of most of the
body’s retinoids (such as vitamin A). Additionally, during liver injury they transition into
an “activated” state characterized by increased proliferation, contractility, and collagen
secretion, contributing to liver fibrosis (81). These are the major cell types involved in
liver function but there are several others including lymphocytes, neuroendocrine cells,
blood cells, and smooth muscle cells (76).
Due to the highly lipogenic nature of the liver, it can store excess lipid as TG-rich lipid
droplets. Hepatocyte lipid balance, or lipid droplet content is determined by four main
processes (82):
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1) Delivery of exogenous lipid to the liver (section 1.3.1). This would include lipid
from circulating free fatty acids and apoB-containing lipoproteins.
2) De novo synthesis of lipid within the liver (section 1.4.2).
3) Export of lipid by VLDL secretion (section 1.3.2).
4) Metabolism of lipid by fatty acid β-oxidation (section 1.4.4).
The rates of 1) and 2) contribute to hepatic lipid storage which is opposed by lipid
removal through the rates of 3) and 4). Hepatic TG is relatively inert and not particularly
harmful. In contrast, free fatty acids and other lipid intermediates can result in
lipotoxicity, so hepatocytes will promote their esterification in TG. However, hepatocytes
have a limited capacity to store TG-rich lipid droplets before hepatic dysfunction can
start to occur.
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Figure 1-4 Liver cell types and structure
The liver and its various cell types are arranged into structures known as lobules. The
hepatic artery and portal vein deliver blood from the arteries and intestine, respectively,
which flows into the sinusoid. The bile duct is located near the hepatic artery and portal
vein to form a portal triad. Blood flow through the sinusoid drains to the central vein and
exits the liver. Liver lobules are organized in hexagonal structure with six portal triads
surrounding a central vein (74-77).
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1.6.2

Non-alcoholic fatty liver disease

Hepatic steatosis occurring in the absence of alcohol is clinically referred as nonalcoholic fatty liver disease (NAFLD). If the rates of lipid delivery to the liver and de
novo lipogenesis within the liver are not matched by rates of fatty acid β-oxidation and
VLDL secretion, then hepatocytes will increase lipid droplet formation and NAFLD will
ensue. NAFLD is thought to be the hepatic manifestation of the metabolic syndrome due
to its tight association with obesity, dyslipidemia, and type 2 diabetes (83). NAFLD
encompasses a spectrum of disorders from simple steatosis to steatohepatitis (covered in
the next section) which can progress to more severe conditions such as cirrhosis, which is
irreversible and greatly increases the risk of developing hepatocellular carcinoma (83).
NAFLD is largely asymptomatic in its early stages, especially when present as only
simple steatosis. The gold standard for diagnosis is a liver biopsy, despite efforts to
develop less invasive diagnostic methods. Liver biopsy is subject to sampling error,
subjective interpretation of results, and a small chance of complications (83–85).
Developing means of non-invasive NAFLD diagnosis has been met with varying degrees
of success and include imaging modalities, plasma markers, and scoring algorithms. The
major drawbacks of these methods is both low sensitivity (false negatives) and specificity
(false positives). Imaging can be done with ultrasound, computed tomography (CT) or
most accurately with magnetic resonance imaging (MRI) (86) as well as derivations of
these technologies such as transient elastography, or FibroScan® (87). Plasma markers
that can be looked at to assess liver function include alanine and aspartate transaminases
(ALT and AST, respectively), albumen, platelet count, glucose, insulin, TG, and
cholesterol (85, 86). There are also many scoring algorithms which take these plasma
measurements into account, in addition to age, gender, body mass index, insulin
resistance and glycemia, hypertension, and the results from the imaging tools previously
mentioned (85, 86). All of these methods for the diagnosis of NAFLD, or more severe
steatohepatitis and fibrosis, are susceptible to giving false positive results (especially with
comorbidities) or simply failing to detect NAFLD, especially when in its earliest stages.
By the time clinicians are presented with enough evidence to warrant a biopsy, the liver
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disease could have progressed to much more advanced and serious stages, described in
the next section.

1.6.3

Non-alcoholic steatohepatitis and inflammation

NAFLD progression to its most serious form, termed nonalcoholic steatohepatitis
(NASH), is in most general terms hallmarked by increased inflammation and fibrosis
(86). Histologically it presents as simple steatosis (as is the case for NAFLD) with the
additions of hepatocyte ballooning, monocyte infiltration, and collagen deposition (not
seen with early NAFLD) (88). The increase in fibrosis and inflammation seen with
NASH greatly increases one’s risk to progress to hepatocellular carcinoma and liver
failure. The features of NASH stem from the lipid imbalances which characterized
NAFLD but when left unchecked these further lead to NASH through several potential
mechanisms. These include lipotoxicity, endoplasmic reticulum (ER) stress, oxidative
stress, immune activity, and endotoxin and cytokine signaling (86), each described briefly
below.

1.6.3.1

Lipotoxicity

When the liver’s mechanisms for mitigating the accumulation of free fatty acids become
overwhelmed, lipotoxicity ensues. Excess fatty acids can induce ER stress, reactive
oxygen species (ROS) production and oxidative stress, and insulin resistance from
lipotoxic intermediates such as diacylglyceride (DAG) and ceramides (89, 90). These
mechanisms collectively increase hepatic inflammation, cellular apoptosis and necrosis,
fibrosis, and the progression of NAFLD to NASH.

1.6.3.2

ER stress

Membrane and secreted proteins are synthesized and folded within the ER lumen. When
the accumulation of unfolded proteins exceeds the ER’s capacity, ER stress ensues. The
ER stress response, or unfolded protein response (UPR) is an adaptive mechanism for
cells to restore intracellular homeostasis. Activation of the UPR results in an overall
reduction in protein synthesis, increased lipogenesis for ER membrane expansion,
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induction of autophagy to recycle unfolded proteins, and the activation of various
inflammatory cascades (89, 91).

1.6.3.3

Reactive Oxygen Species

An increase in reactive oxygen species (ROS) can lead to oxidative stress. ROS can be
generated by lipotoxicity and the UPR which add to the already high ROS production by
hepatocyte fatty acid oxidation (89). Excess oxidative stress can lead to nuclear and
mitochondrial DNA damage and elevated proinflammatory cytokine production (89).

1.6.3.4

Immune responses

The innate immune system plays a major role in NASH development and progression to
more serious diseases of the liver. The temporal relationship of the key events that
culminate in NASH are not well understood. During the development of NASH, there is
an increase in infiltration of circulating immune cells while endogenous Kupffer cells
transition to a proinflammatory or “activated” phenotype. Possibly driving this is the
chronic, low-grade inflammation and elevations in circulating cytokines seen during
obesity, insulin resistance, and the metabolic syndrome (80). Additionally, dietary
components (such as fats and fructose) can augment the microbiota within the gut and
increase the production of endotoxins such as lipopolysaccharide (LPS). The same
dietary factors can increase gut permeability and lead to elevations in circulating
endotoxin concentrations (80, 92). Via the portal vein, endotoxins from the gut will first
go to the liver, where LPS activates cell surface receptors triggering an inflammatory
response (93).
The inflammatory responses of Kupffer cells and other immune cell types throughout the
body are best characterized by an increase in the production and secretion of cytokines
and chemokines (94). Secreted cytokines trigger further inflammatory signaling in liver
cells, the effects of which depend on the cell type. Kupffer cells will increase cytokine
production creating a feed-forward effect. Hepatic stellate cells will enter into their
activated stated where proliferation and collagen synthesis is increased, leading to
fibrosis. In hepatocytes, cytokines can promote lipid accumulation and apoptosis.
Importantly, hepatocyte apoptotic bodies and damage-associated molecular pattern
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molecules (DAMPs) will further trigger inflammatory signaling in the surrounding cells.
Chemokines promote the recruitment circulating immune cells so in the context of
NASH, chemokines with increase the hepatic infiltration of immune cells (80, 94, 95).

1.6.4

Inflammatory signaling pathways

The many stimuli described in the previous section can trigger intracellular signaling
pathways within hepatocytes, Kupffer cells, and other liver cell types which can further
elevate the liver’s inflammatory status. These pathways are sensitive to the various
stimuli implicated in NAFLD and NASH (lipotoxicity, ER and oxidative stress, cytokine
signaling, etc.) and govern stimuli responses (apoptosis, cytokine production, etc.). The
primary molecular pathways that will be discussed here are mitogen-activated protein
kinase (MAPK) and nuclear factor-κB (NF-κB).

1.6.4.1

MAPK pathways

The MAPK pathways are integral to a large number of cellular processes due to the vast
number of signals they detect, and responses they elicit. The MAPK proteins represent a
family of serine and threonine kinases which are often described according to one of
three subgroups: extracellular signal-regulated kinases (ERKs), c-Jun N–terminal kinases
(JNKs), and p38 MAPKs. Each subgroup contains multiple isoforms, as shown in Figure
1-5.
MAPK stimuli include hormones, growth factors, cytokines, DAMPs, pattern associated
molecular pattern molecules (PAMPs), and environmental stress. They are activated by
upstream MAPK kinase (MAP2K) phosphorylation of conserved threonine/tyrosine
residues, which follows prior activation by MAPK kinase kinases (MAP3Ks). This three
tier kinase hierarchy represents what is be the classic model of MAPK signaling. The
numerous functions of MAPK signaling will not be discussed in detail but how the ERK,
JNK, and p38 pathways pertain to inflammation and metabolic dysfunction will be
briefly described below.
The ERK proteins were the first MAPKs to be described and exist in two isoforms, ERK1
and ERK2. As their name suggests, they were originally found to have a role in mitogen
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signaling including some of the mitogenic effects of insulin. In addition to their key role
in growth and differentiation, ERKs have since been found to play a role in innate
immunity and inflammation. The JNK proteins exist in three isoforms, JNK1/2/3 and
were discovered for their ability to phosphorylate the c-Jun transcription factor,
regulating the function of the activating protein 1 (AP1) family of transcription factors.
Compared to ERK1/2, JNK1/2/3 is much more sensitive to environmental stresses and
proinflammatory signaling. Lastly, the p38 MAPKs exist as α, β, γ, and δ isoforms and
like the JNKs, have a greater sensitivity to stress and inflammatory signaling.
Collectively, the MAPKs pathways respond to inflammatory stimuli and environment
stresses to augment insulin sensitivity and inflammatory responses. Insulin sensitivity is
reduced by IRS-1 serine phosphorylation by MAPKs (see section 1.5.3). Inflammatory
responses are augmented though transcriptional regulation via AP1 heterodimers.
Specifically, AP1 dimers can consist of a number of combinations of proteins such as
ATF2, ELK1, SAP1a, c-Jun, and c-Fos. These dimer combinations determine the
promoter targets of AP1, allowing AP1 to regulate a number of processes such as
proinflammatory gene expression. MAPKs can phosphorylate these proteins, altering
their activity or dimer stability (Figure 1-5) (96, 97).

1.6.4.2

NF-κB pathway

The NF-κB pathway transcriptionally regulates anti-apoptotic and proinflammatory
processes. Most notably, active NF-κB directly increases the cytokine and chemokine
gene expression. Extracellular signals such as cytokines, PAMPs, and DAMPs bind to
cell surface receptors including toll-like receptors (TLRs) and tumor necrosis factor
receptors (TNFRs). Signaling through these receptors can activate MAPK and NF-κB
pathways. NF-κB is normally sequestered within the cytoplasm by inhibitor of NF-κB-α
(IκBα) where it is unable to bind the promoters of target genes. Inflammatory signals
from TLRs or TNFRs activate the inhibitor of IκBα kinase (IKK) complex, consisting of
α, β, and γ subunits. Activation of IKKβ through phosphorylation leads to it
phosphorylating IκBα. Phosphorylated IκBα leads to its ubiquitination and degradation,
thus releasing NF-κB which can migrate to the nucleus and promote inflammatory gene
expression (98, 99) (Figure 1-5).
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Figure 1-5 General overview of inflammatory signaling pathways
Intracellular signaling pathways activated in response to different types of inflammatory
stimuli. Extracellular stimuli can include cytokines such as tumor necrosis factor α
(TNFα), interleukin 1β (Il-1β), pathogen associated molecular patterns (PAMPs) such as
lipopolysaccharide (LPS) and foreign DNA, damage associated molecular patterns
(DAMPs) such as oxidized LDL (oxLDL) and ATP, free fatty acids (FFAs), and various
growth factors. Receptors for these stimuli include the IL-1β receptor (IL-1βR), TNF
receptor (TNFR), and toll-like receptor (TLR) families. Intracellular inflammatory
stimuli and damage includes FFAs, diacylglyceride (DAG), ceramides, reactive oxygen
species (ROS), endoplasmic reticulum (ER) stress, and ultraviolet (UV) light. Both
intracellular stimuli and extracellular-receptor mediated stimuli can activate the mitogen
activated protein kinase (MAPK) pathways. The MAPK pathways are activated at the
levels of the MAPK kinase kinases (MAP3Ks) which activate the MAPK kinases
(MAP2Ks) by serine/threonine phosphorylation. MAP2Ks activate the MAPK proteins
by threonine/tyrosine phosphorylation. These include three main families: p38 MAPKs,
c-Jun N–terminal kinases (JNKs), and extracellular signal-regulated kinases (ERKs).
When activated these can regulate many transcription factors by serine/threonine
phosphorylation. These factors form activating protein 1 (AP1) heterodimers (such as
Jun-Jun, Jun-Fos, and Jun-ATF) which can regulate inflammatory gene expression.
Activated MAPKs can also phosphorylate the insulin receptor substrate (IRS) at serine
residues, leading to decreased activity and insulin resistance. Another major pathway is
through the nuclear factor-κB (NF-κB) transcription factor, which is normally bound to
inhibitor of NF-κB-α (IκBα) and sequestered in the cytosol. The inhibitor of IκBα kinase
(IKK) family phosphorylates IκBα, causing its ubiquitination and degradation, releasing
NF-κB, allowing it to translocate to the nucleus and regulate inflammatory gene
expression. Figure created using references (80, 96–114).
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1.7
Modulating Lipoprotein Metabolism - Current and
Potential Drug Targets
Efforts to lessen the onset of atherosclerotic CVD have primarily led to the development
of therapies to lower LDL-C levels. An understanding of the molecular pathways that
determine how the body maintains lipid homeostasis has offered clues as to how these
pathways can be manipulated for therapeutic benefit. Indeed, this has allowed for targetbased drug design to develop several different therapies – some very successful while
others not, and still many more whose clinical potential have yet to be determined.

1.7.1

HMG-CoA reductase

As mentioned in section 1.4.1, HMGCR catalyzes the conversion on HMG-CoA to
mevalonate, the rate-limiting step of cholesterol biosynthesis. Statins inhibit hepatic
HMGCR and thus decrease the intracellular concentrations of cholesterol. This results in
the activation of the sterol-sensing SREBP-2, which upregulates genes involved in
cholesterol synthesis and uptake such as HMGCR, PCSK9, and most importantly LDLR.
The increase in membrane expression of the LDLR enhances the clearance of apoB100containing lipoproteins and thus lowers plasma LDL-C levels (52, 115). Clinically,
statins have demonstrated robust efficacy in preventing CVD and death in several large
cardiovascular outcomes trials and thus are currently the standard of care (8, 10, 116).

1.7.2

Proprotein convertase subtilisin/kexin-9

Proprotein convertase subtilisin/kexin 9 (PCSK9) has gone from its initial discovery to
late stage clinical development all in the last 15 years (117). It was first identified in
patients who inherited a gain-of-function mutation resulting in hypercholesterolemia and
a reduction in LDLR expression (118). Conversely, it was also shown that patients with
loss-of-function mutations had much lower LDL-C and showed protection from CVD
(119). The PCSK9 protein is secreted predominantly from hepatocytes into the
circulation, where is binds to the LDLR. When the LDLR is internalized while bound to
PCSK9, it is degraded instead of being recycled back to the cell membrane surface.
Therefore, total LDLR expression is decreased causing an increase in circulating LDL-C
(120, 121) Since its discovery, monoclonal antibodies have been developed against the
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PCSK9 protein which have been shown to be very effective in lowering LDL-C, even as
much as 60% (122). Interestingly, statins are known to induce SREBP2 activation
causing an increase in PCSK9 and LDLR expression, where inhibition of the latter with
the former likely serving as a negative feedback mechanism. Therefore, PCSK9
inhibition could negate this effect of increased PCSK9 expression and thus work
synergistically in combination with statins to further increase hepatic LDLR expression
and lower LDL-C (117, 121). Large cardiovascular outcomes trials are currently
underway to test if PCSK9 inhibition can protect against CVD.

1.7.3

Niemann-Pick C1-like protein 1

Dietary and biliary cholesterol absorption in the gut takes place at the brush border of
small intestinal cells. Mediating this process is the enterocyte membrane protein
Niemann-Pick C1-like protein 1 (NPC1L1) (123). Ezetimibe inhibits NPC1L1 and thus
reduces intestinal cholesterol absorption and transport to the liver. In the liver this results
in increased LDLR expression, a mechanism similar to that of statins. Ezetimibe as
monotherapy does not lower LDL-C as much as a statin, however it can further lower
LDL-C when used as an add-on to statin therapy (124). Ezetimibe has been in use for
some time but whether its incremental benefit in LDL-C lowering as a combination
therapy translates into improved cardiovascular outcomes was not known until recently.
Compared to simvastatin monotherapy, ezetimibe plus simvastatin gave a small but
significant reduction in LDL-C and improved cardiovascular outcomes (125).

1.7.4

Cholesterol ester transfer protein

As mentioned in section 1.3.4, CETP facilitates the transfer of CE from HDL to TRLs in
exchange for TG. Preventing this exchange results in an elevation in HDL-C while also
lowering LDL-C, so several efforts have been made to therapeutically inhibit CETP. The
first of these attempts was with Pfizer’s torcetrapib, which indeed did increase HDL-C
while also lowering LDL-C in up to Phase III clinical trials. However, in late 2006 Pfizer
announced that it was terminating all further development of torcetrapib and in 2007 it
was revealed that torcetrapib increased CVD events by 25% compared to placebo (126).
This effect was attributed to an increase in blood pressure caused by torcetrapib and not a
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result of CETP inhibition, per se (127). It was still an open question whether the so-called
“HDL hypothesis” (raising HDL-C) was still valid and specifically if CETP inhibition
could still be viable for the prevention of CVD. Further development of three other CETP
inhibitors continued after confirming the absences of any effects on blood pressure (128).
In 2012 Hoffmann-La Roche halted development of dalcetrapib (129) and in 2015 Eli
Lilly did the same with evacetrapib (130) both citing futility due to a lack of efficacy in
preventing CVD. This leaves Merck’s anacetrapib as the remaining CETP inhibitor still
in late stage clinical development (131) although there is a lack of consensus about
whether it should or will remain so (132, 133).
These disappointing clinical findings have led to investigators taking a closer look at the
evidence for CETP inhibition. Strong genetic evidence exists for loss of function variants
resulting in increased HDL-C. However, it is still not known if HDL concentrations play
a causal role in CVD development or if it is just a risk marker, and if raising HDL-C via
CETP inhibition translates into CVD protection (133). Early studies showed that CETP
gene transfer in mice increased atherosclerosis (134, 135) while CETP inhibition in
rabbits was atheroprotective (136–138). However, other studies have found the opposite
to be true (139, 140). In light of the inconsistencies in the animal studies it is important to
note that mice do not express CETP and studies where mice express transgenic human
CETP are unlikely to be representative of normal human metabolism. Additional studies
have looked at plasma CETP function and concentration and its relationship with CVD
risk. The six prospective studies that have looked at this have all showed an inverse
relationship between CVD incidence and CETP activity (141–146). So if low CETP
activity actually increases cardiovascular risk, it is hard to see the rationale for continued
development of CETP inhibitors and has led some to argue that continuing clinical trials
poses a risk to patients (147, 148).

1.7.5

AMP-activated protein kinase

AMP-activated protein kinase (AMPK) is a cell-autonomous sensor of cellular energy
status and regulator of metabolic homeostasis. It is a highly conserved heterotrimeric
serine/threonine kinase. Each heterotrimer consists of an α catalytic subunit, β scaffolding
subunit, and γ regulatory subunit, with multiple isoforms existing for each (α1, α2, β1,
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β2, γ1, γ2, γ3). These isoforms allow for the formation of up to 12 potential
heterotrimers, and expression patterns differ in a tissue and species dependent manner.
For example, α1β2γ1and α2β2γ1 are the predominant isoforms in human liver and
muscle, respectively, while α2β1γ1 predominates in rat liver (149, 150). AMPK is
acutely sensitive to changes in intracellular energy status due to its ability to detect
changes in AMP:ADP:ATP ratios. In response to low intracellular energy status under
conditions such as hypoxia or nutrient deprivation, AMPK is activated by threonine-172
phosphorylation of the α subunit along with AMP binding to the γ subunit. Active AMPK
phosphorylates a myriad of targets, triggering several metabolic responses (Figure 1-6).
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Figure 1-6 Hepatic AMPK targets
Activated AMPK phosphorylates many targets to regulate cellular energy balance.
Activated catabolic processes include autophagy, mitochondrial biogenesis, and fatty acid
β-oxidation. Inhibited anabolic processes include cholesterol synthesis, fatty acid
synthesis, protein synthesis, and gluconeogenesis. ACC, acetyl-CoA carboxylase; CRCT,
cAMP response element binding protein-regulated transcription coactivator; HMGCR, 3hydroxy-3-methylglutaryl-CoA reductase; mTORC1, mammalian target of rapamycin
complex 1; PGC-1α, peroxisome proliferator-activated receptor γ coactivator 1-α;
RAPTOR, regulatory associated protein of mTOR; SREBP, sterol regulatory element
binding protein; TSC, tubular sclerosis complex; ULK, unc-5 like kinase.
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Ultimately, AMPK signaling augments cellular metabolism towards catabolic, ATPproducing pathways, while concomitantly inhibiting non-essential anabolic, ATPconsuming pathways. Therefore, AMPK activation can promotes processes such as fatty
acid β-oxidation and glycolysis while suppressing fatty acid synthesis and
gluconeogenesis, making it a compelling target for treating conditions relating to
cardiovascular disease, diabetes, inflammation, and even cancer (151–153). However,
there are no therapies currently in clinical use that directly target AMPK. There is
evidence that AMPK plays a role in the mechanism of action of several widely used
drugs such as the aspirin metabolite salicylate (154–156) and metformin (157–160).
Of the many targets of AMPK, the most notable is possibly acetyl-CoA carboxylase
(ACC) due to is key roles in fatty acid synthesis and β-oxidation (sections 1.4.2 and
1.4.4, respectively). Specifically, AMPK phosphorylation of ACC reduces its ability to
produce malonyl-CoA, thus providing less substrate for fatty acid synthesis while also
relieving inhibition on fatty acid β-oxidation. Malonyl-CoA inhibits Cpt1α and βoxidation, and decreases in malonyl CoA relives this inhibition. Another target is
HMGCR, which like ACC is also inhibited by AMPK phosphorylation. However,
although these two proteins were the first discovered targets of AMPK (161, 162), there
is still very little understanding of the physiological relevance of HMGCR inhibition by
AMPK phosphorylation (163). The duel inhibition of ACC and HMGCR by AMPK
likely explains its ability to limit both fatty and cholesterol synthesis, respectively.

1.7.6

ATP-citrate lyase

ATP-citrate lyase (ACL) is responsible for the synthesis of cytosolic acetyl-CoA, a
central metabolite in many metabolic pathways. It utilizes cytosolic citrate, CoASH, and
ATP to generate acetyl-CoA plus oxaloacetate. Cytosolic citrate can come from transport
out of the mitochondria, since it as a citric acid cycle intermediate, or can be synthesized
within the cytosol from glutamate. As mentioned in section 1.4, cytosolic acetyl-CoA is a
substrate for both fatty acid and cholesterol synthesis (Figure 1-7). This has been
demonstrated with ACL knockout models and inhibitors resulting in suppressed de novo
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fatty acid and cholesterol synthesis. Additionally, ACL can be nutritionally regulated by
two mechanisms. First, it’s gene is an SREBP target and so it is upregulated in response
to insulin. Second, it has been shown to be phosphorylated and activated by AKT (164–
168).
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Figure 1-7 Mitochondrial and cytosolic acetyl-CoA as both a substrate and product
Hepatic acetyl-CoA exists in multiple intracellular pools. The mitochondrial and nucleocytosolic pools are the most significant but there does exist peroxisomal and intrareticular
pools as well (not shown). Mitochondrial acetyl-CoA can be derived from many sources
including pyruvate (from glycolysis), free fatty acids (from β-oxidation), and amino acid
metabolism. The majority of this mitochondrial acetyl-CoA is metabolized in the
tricarboxylic acid (TCA) cycle or used for ketone body synthesis. To migrate between the
mitochondrial and nucleo-cytosolic pools, acetyl-CoA must either be converted to citrate
or utilize the carnitinepalmitoyl transferase system (not shown). Most cytoplasmic acetylCoA is synthesized from citrate by ATP-citrate lyase but can also be synthesized from
acetate by acyl-CoA synthetase. The nucleo-cytosolic pool can be used for the synthesis
of fatty acids or cholesterol or for protein acetylation. Acetyl-CoA carboxylase (ACC)
catalyzes the conversion of acetyl-CoA to malonyl-CoA which is used by fatty acid
synthase (FAS) to generate acyl-CoAs. Acetyl-CoA acetyltransferase creates acetoacetylCoA which is converted by 3-hydroxy-3-methylglutaryl-CoA synthase (HMGCS) to
generate HMG-CoA for cholesterol synthesis.
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1.7.6.1

Bempedoic acid

Bempedoic acid (BA; also known as ETC-1002 or 8-hydroxy-2,2,14,14tetramethylpentadecanedioic acid) is an ACL inhibitor in clinical development for the
treatment of hypercholesterolemia. It resembles a fatty acid analogue and was identified
in a drug screen for its ability to inhibit cholesterol and fatty acid synthesis in vivo (169).
Results from up to Phase IIb clinical trials have consistently shown a 30% lowering of
LDL-C in hypercholesterolemic patients and an unanticipated 40% lowering in high
sensitivity C-reactive protein (hsCRP) with BA monotherapy (168, 170). To date clinical
studies have been completed in over 1000 subjects with more than 700 receiving BA
across 10 clinical trials (3 Phase I, 7 Phase II). The majority of patients studied had
hypercholesterolemia but BA has also been studied in patients with Type 2 Diabetes,
statin intolerance, hypertension, or on stable statin or ezetimibe therapy (171–176). There
is evidence in rodent models that BA may improve metabolic dysregulation associated
with the metabolic syndrome, including insulin resistance, hepatic steatosis, atherogenic
dyslipidemia and tissue inflammation (177–179).
BA appears to target the liver, where it inhibits ACL and may also activate AMPK
(Figure 1-8) (177). To inhibit ACL, BA must be formed into a coenzyme-A thioester by
acyl-CoA synthase (ACS). It was recently shown that the specific ACS isoform that
catalyzes BA-CoA formation has high expression in human liver while showing no
expression in muscle, explaining how BA’s mechanism is liver-specific (180). BA-CoA
binds to and inhibits ACL in a manner competitive for coenzyme-A, resulting in a rapid
decrease in acetyl-CoA and HMG-CoA while raising cytosolic citrate both in vitro and in
vivo (168, 177). Activation of AMPK by BA phosphorylates and inhibits ACC and
HMG-CoA reductase likely contributing to the observed inhibition of fatty acid synthesis
and cholesterol synthesis, respectively, both in vitro and in vivo (Figure 1-6). Inhibition
of ACC depletes the malonyl-CoA pool for fatty acid synthesis by FAS and relieves the
inhibition of CPT1α-mediated β-oxidation by malonyl-CoA. Increased β-oxidation was
observed in primary rat hepatocytes and in vivo results demonstrated increased plasma βhydroxybutyrate, suggesting increased hepatic β-oxidation (168, 169).
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Figure 1-8 Hepatic effects of bempedoic acid.
Bempedoic acid (BA) must first to converted to a CoA thioester (BA-CoA) to inhibit
ATP-citrate lyase (ACL). This reduces cytosolic acetyl-CoA providing less substrate for
sterol and fatty acid synthesis. BA can also activate AMPK by threonine phosphorylation
of the α subunit. This results in the reduction of ACC activity and thus malonyl-CoA
synthesis. As a result, fatty acid synthesis is reduced and β-oxidation is increased.
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Studies in mice, rats, and hamsters have shown that BA increases hepatic protein
expression of peroxisome proliferator activated receptor (PPAR) γ-coactivator 1α
(PGC1α), a regulator of mitochondrial biogenesis, and elevates plasma levels of βhydroxybutyrate (168). This occurred while also decreasing plasma cholesterol, TG,
glucose and insulin, as well as hepatic fat content, fatty acid synthesis, and cholesterol
synthesis (169, 177, 178, 181). In cultured human macrophages and murine adipose
tissue, BA down-regulated proinflammatory MAPK signaling pathways and decreases
cytokine and chemokine secretion through activation of AMPK signaling (178). The
effect that BA has on atherosclerotic lesion development in Ldlr-/- mice fed a high-fat,
cholesterol-containing diet, remains to be elucidated.

1.8

Model to be used

Mouse models are very common for studying several of the abnormalities associated with
the metabolic syndrome. The C57BL/6 mouse is by far the most utilized strain due to its
increased susceptibility to metabolic diseases when compared to other inbred strains of
mice (182, 183). Using the C57BL/6 background, knockout of the LDLR gene (Ldlr)
results in some susceptibility to atherosclerosis when fed a low fat chow diet, but plaques
usually do not develop beyond small fatty streaks. Ldlr-/- mice fed a high fat, cholesterol
containing diet however, develop far more severe atherosclerotic lesions over a
reasonably short period of time due to the large increase in plasma cholesterol
concentrations. These lesions are usually characterized as being large lipid-rich and foam
cell-predominant and readily develop in the aortic sinus and aorta. This is a widely used
model for studying atherosclerosis (184, 185). Additionally, this mouse models exhibits
obesity, dyslipidemia, NAFLD development and inflammation when fed a diet with
added fat and cholesterol (186–189).

1.9

Hypothesis and Scope of Thesis

In the current study, the ability of BA to protect against CVD through the prevention of
CVD-associated risk factors was investigated. Specifically, using a murine model of the
metabolic syndrome and atherosclerosis, this work sought to determine if targeting
hepatic ACL and AMPK with BA could prevent the onset of abnormalities associated the
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metabolic syndrome such as increased adiposity, insulin resistance, dyslipidemia, hepatic
steatosis, inflammation and atherosclerosis. These abnormalities are linked to the process
of atherogenesis. Therefore, the hypothesis to be tested was that in Ldlr-/- mice fed an
atherogenic diet high in fat and cholesterol, BA treatment would prevent the onset of
obesity, dyslipidemia, hepatic steatosis, and insulin resistance, attenuate inflammation,
and thus prevent the development of atherosclerosis.
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2

Methods
2.1

Animals and diets

Male, 8-week old Ldlr-/- C57BL/6 mice (B6.129S7-Ldlrtm1Her/J; Stock# 002207,
Jackson Laboratory, Bar Harbour, ME) were maintained at 23°C on a 12-hour dark/light
cycle and cared for in accordance with the Canadian Guide for the Care and Use of
Laboratory Animals. All experimental procedures were approved by the Animal Care
Committee at the University of Western Ontario (protocol number: 2012-028). 120 mice
(n = 24/group) were fed ad libitum either control diets or diets supplemented with
Bempedoic acid (BA, also known as ETC-1002; Ricerca Biosciences, Concord, OH) for
12 weeks. Diet compositions are shown on Table 2-1. Five groups of mice (see Figure
2.1) received either a purified rodent chow control diet (14% of calories from fat, Harlan
Teklad T8604, Madison, WI), a high-fat cholesterol-containing diet (HFHC; 42%
calories from fat and 0.2% cholesterol, Harlan Teklad TD09268) or HFHC supplemented
with approximately 3, 10 or 30 mg of BA per kg body weight per day (mg/kg BA). BA
was solubilized in ethanol and mixed with HFHC at the appropriate dose, followed by air
drying of ethanol. Fresh food was provided twice per week with updated BA doses,
which were based on the caloric intake and body weight measurements determined the
previous day. Daily caloric intake was measured as the difference between the mass of
food provided minus the mass of food remaining, which was then divided by change in
time and multiplied by the caloric density of the food (chow = 3.1 kcal/g, HFHC = 4.5
kcal/gram).
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Table 2-1: Mouse diets
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Figure 2-1 Study design
Bloods samples were taken at baseline and weeks 4, 8, and 12. Metabolic cage
experiments were performed at week 9. Micro (μ) CT scans were performed at week 10.
Glucose tolerance test (GTT) and insulin tolerance test (ITT) were performed at week 11.
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2.2

Blood and tissue collection

All mice were fasted 6 hours before sacrifice or blood collection. Blood was collected at
baseline and weeks 4, and 8 via a small nick in the tail vein at which time blood glucose
was measured by glucometer (Bayer Contour Blood Glucose Monitoring System, Bayer
Healthcare, Mississauga, ON). At sacrifice, mice were anesthetized with ketaminexylazine (100 μg/g Ketamine Hydrochloride: Bioniche Animal Health Canada Inc.
Belleville ON and 10 μg/g Xylazine: Bayer Healthcare, Animal Health Division, Bayer
Inc. Toronto ON) and tissue dissections were performed via midline incision. A small
section of liver tissue was harvested first by freeze-clamping, using pliers chilled in liquid
nitrogen (190). Blood was collected in EDTA syringes by cardiac puncture, and plasma
collected after centrifugation at 12 000 RPM at 4°C. Plasma samples were stored at 20oC. Epididymal adipose tissue, remaining liver, heart and aorta where then dissected
and cleaned. For histological analyses, samples of liver and heart (containing the aortic
root) were placed in Optimum Cutting Temperature (OCT) Compound (Sakura Finetek,
USA Inc. Torrance, CA USA), frozen on dry ice and stored at -80oC. Remaining tissues
were snap-frozen in liquid nitrogen and stored at -80°C.

2.3

Plasma analyses

Plasma was analyzed for cholesterol (Wako, VWR, Mississauga, ON) and TG (Roche
TG/GB, glycerol blanked, Roche Diagnostics, Laval QC) concentrations by enzymatic
assays as described previously (191). Concentrations of insulin (ALPCO Diagnostics,
Windham, NH) and serum amyloid-A (SAA) (Invitrogen, Life Technologies,
Mississauga, ON) were determined by mouse specific ELISA as per manufacturer’s
instructions. Fast performance liquid chromatography (FPLC) was performed on fresh
EDTA-plasma using an AKTA purifier and a Superose 6 column as previously described
(191). FPLC separates plasma contents on the basis of size, thus allowing for the
separation and identification of the lipoproteins present in a sample. Cholesterol and TG
measurements were performed on samples from each eluted fraction as described above.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were analyzed
using enzymatic kinetic rate reactions (Roche Diagnostics) performed at the London
Health Sciences Centre Core Laboratory.
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2.4

Glucose and insulin tolerance tests

Glucose and insulin tolerance testing were performed after 11 weeks on diet, to measure
glucose disposal and insulin sensitivity, respectively. For glucose tolerance tests (GTTs),
mice were fasted for 6 hours prior to receiving 1g/kg glucose by i.p. injection of a 15%
glucose, 0.9% NaCl solution. For insulin tolerance tests (ITTs), mice were fasted for 5
hours prior to injection of 0.6 IU/kg Novolin ge Toronto (Novo Nordisk) i.p. Blood
glucose measurements by glucometer were determined on samples taken up to 120
minutes (GTT) or 60 minutes (ITT) post-injection and reported as blood glucose vs time
or glucose change from baseline vs time.

2.5

Metabolic analyses

Oxygen consumption (VO2, L/kg/hour), carbon dioxide production (VCO2, L/kg/hour),
and respiratory exchange ratio (RER, VCO2/VO2) were measured using the
Comprehensive Laboratory Animal Monitoring System (CLAMS, Columbus
Instruments, Columbus, OH). Mice had continuous access to food and water and after a
24-hour acclimatization period data was collected for up 48 hours.
For fatty acid oxidation, fresh liver was homogenized in 0.1 M phosphate buffer
containing 0.25 M sucrose and 1 mM EDTA. Liver homogenates were incubated for 30
min at 37ºC in a buffer containing 150 mM KCl, 10 mM Hepes (pH 7.2), 5 mM Tris
malonate, 10 mM MgCl2, 1 mM carnitine, 0.15% Fatty-Acid Free Bovine Serum
Albumen (Sigma Aldrich, Oakville, ON), 5 mM ATP and 50 µM (µCi) 3H-palmitate
(Perkin Elmer, Waltham, MA) complexed with FAF-BSA. Reactions were stopped with
200 µL 0.6 N perchloric acid and unreacted fatty acids extracted with n-hexane. 3H2O in
the aqueous phase was measured by liquid scintillation counting (191).
Fatty acid and cholesterol synthesis were measured following i.p. injection of
radiolabeled acetic acid (Amersham Canada Ltd). Briefly, mice fasted for 6 hours were
injected with 20 µCi of [1-14C]-acetic acid and sacrificed 1 hour later. Tissues (500 mg)
were extracted in chloroform:methanol and incorporation of [1-14C]-acetic acid into fatty
acid and cholesterol were assayed as described previously (191).
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2.6

Micro-computed tomography imaging

Whole-mouse composition analysis was done by micro-computed tomography (μCT)
imaging using a Locus Ultra μCT scanner (GE Healthcare, London, ON) after mice were
on diet for 10 weeks. Total adipose volume was measured using MicroView 2.2 with
threshold values of -380 to -30 Hounsfield Units to identify adipose tissue (192, 193).

2.7

Tissue sectioning and histology

Tissue histological and morphological analysis were performed using hearts or liver
frozen in OCT and stored at -80°C (194, 195). Frozen serial sections were prepared with
a Leica CM 3050S cryostat to cut 10 and 8 μm thick sections for heart and liver,
respectively. Slides were stained with hematoxylin and Eosin (H&E), oil red-O (ORO,
Sigma Aldrich, Oakville, ON), or picrosirius red. Adjacent slides were analyzed by
immunohistochemistry (IHC) for CD68, cleaved caspase 3 (CC3), or smooth-muscle αactin (SMA) as described previously (195), see Table 2-2 for antibody information.
Briefly, slides were fixed in acetone followed by air drying, rehydrating in phosphate
buffered saline (PBS) and blocking with 2% Fatty-Acid Free Bovine Serum Albumin
(Sigma Aldrich, Oakville, ON) in PBS. Primary (Table 2-2) and biotinylated secondary
(Table 2-3) antibody incubations were performed in blocking solution. Peroxidase
blocking with 3% hydrogen peroxide was followed by incubation with the ABC reagent
(ABC Elite Standard Kit, Vector Laboratories, Burlington, ON). Slides were exposed to
the DAB substrate (Peroxidase substrate kit, Vector Laboratories) and counterstained in
hematoxylin (Sigma-Aldrich).
Within atherosclerotic lesions, areas positive for ORO, CD68 and SMA were measured
with ImageJ 1.50 (National Institutes of Health) and expressed as percent of total lesion
area. Areas positive for picrosirius red were measured with ImageJ using MRI Fibrosis
Tool (196) and expressed as percent of total lesion area. Lesion CC3-positive nuclei and
total nuclei were counted with ImageJ using Color Deconvolution (197, 198) and
expressed as percent CC3 positive nuclei.
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2.8

Tissue lipid analysis

Liver and aortic tissues were weighed and lipids extracted using the chloroform:methanol
(2:1) method of Folch, et al (199). Following extraction, samples and standards were
dried under N2 gas and solubilized in chloroform with 1% Triton X-100. Following
drying under N2 gas again, samples were resolubilized in water and levels of
triacylglycerol (TG), total cholesterol (TC) and free cholesterol (FC) were measured by
enzymatic assay. Lipid measurements were normalized to wet tissue weight. Cholesteryl
ester (CE) was determined by the difference between TC minus FC (194).

2.9

Tissue gene expression

Quantitative real-time PCR (qRT-PCR) was performed on RNA isolated from liver or
aorta using TRIzol® (Life Technologies, Burlington, ON). Reverse transcription into
cDNA was performed using the High Capacity Reverse Transcription kit (Applied
Biosystems, ABI). All primer and probe sets were from Applied Biosystems (Streetsville,
CA) except Srebf1c (200). The probe and primer sequences for Srebf1c were designed
using Primer Express 2.0 (ABI). Primers were obtained from Sigma-Genosys (Forward
Primer: CAGGCCCGGGAAGTCACT; Reverse Primer:
GACCACGGAGCCATGGATT) and the probes from ABI (Probe: FAMATTTGAAGACATGCTCCA-MG). All qRT-PCR assays were previously optimized and
known to work for murine liver and aortic tissues.

2.10

Tissue protein expression

Frozen full-length aorta or freeze clamped liver samples (~50mg) were homogenized as
previously described (195). Proteins were separated on 4-15% acrylamide gels (Bio-Rad)
by SDS-PAGE and transferred to Immobilon-FL (EMD Millipore, Darmstadt, Germany)
PVDF membranes. Primary antibodies were used for phosphorylated and total AMPK,
ACC, ERK1/2, p38, JNK1/2, IKKαβ, and IκBα along with β-actin. Detailed information
of primary antibodies is shown in Table 2-2. Phosphoproteins were analyzed using both
phospho-specific and total antibodies on the same blot, with antibodies raised in different
species (rabbit, mouse, or goat). Appropriate secondary antibodies (Table 2-3) conjugated
to fluorophores of different emission wavelengths (IRdye-800CW or IRdye680RD, LI-
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COR Biosciences, Lincoln, NE) were multiplexed to allow for simultaneous detection of
phosphorylated and total proteins. A LI-COR Odyssey Fc scanner (LI-COR Biosciences)
was used to detect the near-infrared emission signals (700 and 800 nm wavelength)
produced after laser excitation of the conjugated fluorophores. Image Studio 5.0 (LI-COR
Biosciences, Lincoln, NE) was used for signal quantitation. Phosphoproteins were
normalized to loading control (total protein of interest) and expressed as fold change
compared to chow-fed mice. Β-actin was also probes for each blot a visual determination
of equal loading. Blots were optimized to ensure signal was in a linear range.

2.11

Statistical analyses

All data are expressed as means +/- SEM. Statistical analyses were performed using
GraphPad Prism 6. A One-way ANOVA was used to test for differences between groups
of three or more followed by Tukey’s post-hoc test. A two-tailed t-test was used to test
for differences between two groups. A Two-way ANOVA was used to test for differences
between groups when data was collected over a series of timepoints, followed by a
Tukey’s post-hoc test. P < 0.05 was deemed statistically significant as represented by
letters comparing three or more groups.
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Table 2-2 Primary antibodies used for Western blotting and IHC
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Table 2-3 Secondary antibodies used for Western blotting and IHC
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3

Results
3.1
Bempedoic acid attenuates the HFHC-induced
elevation in body weight and adiposity

Male, 8 week old Ldlr-/- mice showed no differences in daily caloric intake between any
groups fed HFHC ± BA for 12 weeks, while chow-fed mice had significantly lower
caloric intake compared to all groups (Figure 3-1A). Any group receiving the HFHC diet
showed a significantly increased gain in body weight when compared to chow-fed mice
(Figure 3-1B). Compared to HFHC feeding alone, mice fed 3 and 10 mg/kg BA displayed
no difference in body weight while mice treated with 30mg/kg BA had a significantly
lower gain in body weight compared to mice fed HFHC (Figure 3-1BC). 30 mg/kg BA
appeared to reduce body weight through a reduction in adiposity as epididymal fat pad
mass measured at sacrifice was significantly less than HFHC alone while 3 and 10 mg/kg
BA showed no change (Figure 3-1D). Additionally, μ-CT measurements of body
composition after 10 weeks on diet showed an attenuation in whole body adiposity with
30 mg/kg BA with no effect on lean or skeletal tissue mass (Figure 3-1E).

3.2

Bempedoic acid prevents hyperlipidemia

Plasma cholesterol and TG concentrations were elevated (5-fold and 4-fold, respectively)
in mice fed the HFHC diet compared to mice fed chow. Hypercholesterolemia was
significantly attenuated with both 10 and 30 mg/kg BA but not 3 mg/kg BA (Figure 32A) and hypertriglyceridemia was significantly attenuated with all three doses of BA
(Figure 3-2B). Cholesterol and TG concentrations in plasma lipoproteins separated by
FPLC revealed that the HFHC diet greatly elevated the VLDL to LDL fractions
compared to chow. Reductions in plasma lipids with 30 mg/kg BA took place primarily
in the VLDL fractions with some effects observed on IDL, LDL, and HDL cholesterol
fractions (Figure 3-3).
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Figure 3-1: Effects of BA on body weight and adiposity.
Average daily caloric intake based on grams of food over the course of the 12-week study
(A) (n=22-24). Weekly body weight measurements taken throughout the 12-week study
(B) (n=22-24). Change in body weight from baseline to week 12 (C) (n=22-24).
Epididymal fat pad mass taken at sacrifice (D) (n=22-24). Total whole body adipose,
lean, and skeletal tissue mass measured by micro-CT scanning (D) (n=8). Data are means
± SEM, different letters indicate statistical differences by one-way (A, C-E) or two-way
(B) ANOVA, P < 0.05. Statistical differences in (B) are for the whole curve.

59

60

Figure 3-2: Effects of BA on plasma lipids
Plasma cholesterol (A) and triacylglycerol (B) concentrations from samples taken every 4
weeks (n=12). Data are means ± SEM, different letters represent statistical differences of
whole curves by two-way repeated measures ANOVA, P < 0.05.
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Figure 3-3: FPLC analysis of the effects of BA on plasma lipids.
Fast-performance liquid chromatography (FPLC) fractions from plasma collected after 12
weeks on diet, analyzed for cholesterol (A) and triacylglycerol (B) concentrations (n=512). Area under the curve (AUC) values for very low-density lipoprotein (VLDL)
(fractions 5-9) and low-density lipoprotein (LDL) (fractions 10-19) analyzed by one-way
ANOVA, P < 0.05. All data are means ± SEM.
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3.3
Bempedoic acid prevents hepatic lipid
accumulation
The HFHC diet caused significant increases in hepatic TG, TC, FC, and CE compared to
chow feeding alone. This effect was mirrored with the 3 mg/kg BA group which
significantly elevated all measured lipids compared to chow-fed mice while showing no
significant differences compared to the HFHC-fed group. TG, TC, FC, and CE were
significantly lowered by both 10 and 30 mg/kg BA compared to HFHC. Interestingly, BA
at 10 and 30 mg/kg showed no significant differences in liver lipid content compared to
those in chow-fed mice (Figure 3-4A-D). These results were reflected in the liver
histology when stained for neutral lipids with ORO (Figure 3-4E).

3.4
Bempedoic acid influences multiple metabolic
pathways in the liver
It was observed that there was a dose-dependent increase in liver weight despite the large
reductions in lipid content (Figure 3-5A). Plasma ALT and AST concentrations showed
no significant changes between all groups suggesting normal liver function (Figure 35BC).
To further understand the mechanism of action of BA in the liver, analyses of gene and
protein expression were carried out. BA has been previously demonstrated to activate the
AMPK pathway in rodent liver (177). This was assessed in mice treated with 30 mg/kg
BA by Western blotting for phosphorylation (p) of both AMPK and its target ACC. Both
pAMPK and pACC were suppressed in the liver of HFHC-fed mice compared to mice
fed chow. Treatment with 30 mg/kg BA reversed this effect resulting in significantly
increased pAMPK and pACC relative to the HFHC diet alone (Figure 3-6). Additionally,
compared to chow and 30 mg/kg BA, the HFHC diet unexpectedly appeared to increase
total AMPK protein levels. This increase was not quantified and how this should be
interpreted remains uncertain.
Hepatic expression of genes involved in fatty acid β-oxidation were analyzed by qRTPCR. Ppara and its target genes, Cpt1a and Acox were generally increased with both 10
and 30 mg/kg BA groups (Figure 3-7A). There was a particularly strong effect on Acox
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expression, which is entirely regulated by PPARα activity (57). The HFHC diet induced a
large elevation in the lipogenic transcription factor Srebf1c compared to the chow diet
and this was significantly attenuated in 30 mg/kg BA-treated mice (Figure 3-7B).
Interestingly, the hepatic expression of other lipogenic genes was generally increased
with BA treatment compared to the HFHC diet alone. Specifically, when compared to
livers from HFHC-fed mice alone, 30 mg/kg BA significantly increased the expression of
Acacb and Fasn while trends were present for the remaining genes (Srebf2, Acaca,
Hmgcr, and Pcsk9) with the exception of Acly (Figure 3-7B). This is possibly due to a
compensatory feedback response resulting from inhibition of ACL, reduced intracellular
sterols, and increased SREBP-2 activity.

3.5

Bempedoic acid improves hepatic lipid metabolism

Hepatic lipid metabolism was assessed biochemically by measuring rates of hepatic fatty
acid β-oxidation and fatty acid synthesis. Compared to chow-fed mice, HFHC feeding
resulted in a small nonsignificant reduction in β-oxidation of 3H-palmitic acid and a large
significant increase in 14C-acetic acid incorporation into fatty acids (Figure 3-8AB). 30
mg/kg BA significantly enhanced β-oxidation compared to chow and HFHC feeding
while also significantly reducing fatty acid synthesis when compared to HFHC alone
(Figure 3-8AB). These metabolic improvements are consistent with activated AMPK and
reduced SREBP-1c gene expression. Metabolic cage experiments were performed to
measure respiratory exchange ratio (RER, a measure of glucose versus lipid fuel
utilization) and respiration rates (VO2 and VCO2). Chow-fed mice had a significantly
higher RER during the dark cycle compared to the HFHC and 30 mg/kg BA groups. The
high RER in the mice fed chow indicates a preference towards carbohydrate metabolism
reflecting their carbohydrate-based diet. The lower RER values observed in the HFHC
and 30 mg/kg BA mice were not different from one another and reflect the high lipid
content in the diets of these groups. Respiration rates (VO2 and VCO2) displayed small
trends towards reduced rates in HFHC-fed mice compared to the chow and 30 mg/kg BA
groups but no changes were significant (Figure 3-8CD). This suggests that any potential
differences in energy expenditure were not large enough to be detected.
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Figure 3-4: Effects of BA on hepatic lipids.
Liver free cholesterol (FC), cholesteryl ester (CE), total cholesterol (TC), and
triacylglycerol (TG) (A-D) (n=14). Oil red-O (ORO) staining of liver tissue (E). Data are
means ± SEM, different letters represent statistical differences by one-way ANOVA, P <
0.05.
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Figure 3-5: Effects of BA on liver size and function
Liver mass measured at sacrifice (A) (n=24). Plasma ALT (B) and AST (C) values (n=8).
Data are means ± SEM, different letters represent statistical differences by one-way
ANOVA, P < 0.05.
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Figure 3-6: Effects of BA on the AMPK signaling pathway.
Representative immunoblots of biological replicates for phospho- and total AMPK and
ACC (A) with quantitations by densitometry shown below (B) (n=7-8). Data are means ±
SEM, different letters indicate statistical differences by one-way ANOVA, P < 0.05.
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Figure 3-7: Hepatic effects of BA on metabolic gene expression.
Hepatic gene expression of peroxisome-proliferator receptor alpha (Ppara) and its targets
carnitinepalmitoyl transferase 1a (Cpt1a) and acyl-CoA oxidase (Acox) (A) and lipogenic
genes sterol response element-binding protein (SREBP)-1c (Srebf1c), SREBP-2 (Srebf2),
acetyl-CoA (ACC)-1 (Acaca), ACC-2 (Acacb), ATP-citrate lyase (Acly), fatty acid
synthase (Fasn), 3-hydroxy-3-methylglutary-CoA reductase (Hmgcr), and proprotein
convertase subtilisin/kexin type 9 (Pcsk9) (B) (n= 8-12). Data are means ± SEM,
different letters indicate statistical differences by one-way ANOVA, P < 0.05.
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Figure 3-8: Effects of BA on hepatic lipid metabolism.
Hepatic β-oxidation (FAO) of 3H-palmitic acid into 3H2O (A) and hepatic fatty acid
synthesis (FAS) measured by incorporation of 14C-acetic acid into 14C-fatty acids (B)
(n=8). Metabolic cage measurements of light and dark cycle volume of oxygen consumed
(VO2) and carbon dioxide produced (VCO2) (C), and respiratory exchange ration RER
(D) (n=6-12). Data are means ± SEM, different letters represent statistical differences by
one-way ANOVA P < 0.05.
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3.6
Bempedoic acid prevents impaired glucose
homeostasis
Fasting blood glucose and plasma insulin were measured over the duration of the study at
baseline and weeks 4, 8, and 12. By week 12, blood glucose for the chow-fed mice was
significantly less than the HFHC-fed mice (Figure 3-9A). Mice treated with 30 mg/kg BA
also showed a significant reduction in blood glucose compared to HFHC, while 3 and 10
mg/kg BA had no effect (Figure 3-9A). Plasma insulin concentrations were significantly
elevated in the HFHC and 3 mg/kg BA groups compared to chow fed mice, whereas 30
mg/kg BA significantly attenuated plasma insulin to levels similar to those in chow-fed
mice (Figure 3-9B).
Glucose and insulin tolerance tests showed reduced glucose and insulin sensitivity in
HFHC-fed mice compared to chow-fed mice. In mice treated with 10 and 30 mg/kg BA,
glucose and insulin tolerance improved (Figure 3-10AB). However, when the data was
expressed as the change from baseline these effects were lost (Figure 3-10CD).

3.7
Bempedoic acid reduces inflammatory marker
expression
To examine the effects of BA on inflammation, gene and protein expression analyses
were used to assess proinflammatory signaling pathways in liver and aortic tissue. The
MAPK (p38, ERK, and JNK) and NFκB (IKK and IκBα) signaling cascades link the
effects of inflammatory stimuli to a cellular response, usually through a transcriptional
mechanism. These inflammatory pathways have been suggested to play a role in
pathologies associated with the metabolic syndrome, such as insulin resistance. In liver,
the HFHC diet had little influence in MAPK signaling compared to chow. Mice treated
with 30 mg/kg BA showed significantly decreased phosphorylation of p38 and ERK1/2
compared to both chow and HFHC alone (Figure 3-11). In the aorta, the HFHC diet
significantly increased JNK phosphorylation compared to chow, an effect that was
attenuated with 30 mg/kg BA (Figure 3-12). The remaining MAPKs showed minimal
differences in phosphorylation between the chow, HFHC, and 30 mg/kg BA groups.
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Phosphorylation of IKK and IκBα, regulators of NFκB activation, was minimal for all
groups and also showed no differences (Figure 3-11, 3-12).
Under inflammatory conditions, such as those seen with HFHC feeding, tissues will
display an increase in classically activated macrophage (M1, proinflammatory) gene
expression and lower alternatively activated macrophage (M2, reparative and antiinflammatory) gene expression. This was observed in the livers and aortae of HFHC-fed
mice for several of the genes measured when compared to mice fed chow alone (Figure
3-13A). In liver, this effect was attenuated with 30 mg/kg BA for all M1 genes measured
and was statistically significant for Tnf and Ccl3 (Figure 3-13A). In aortic tissue of
HFHC-fed mice, M1 gene expression was elevated. Treatment with both 10 and 30
mg/kg BA decreased mean expression of these genes, but this effect did not reach
statistical significance (Figure 3-13B). However, when the effects of BA treatments on all
aortic M1 genes were analyzed there was a significant effect of the drug on overall M1
gene expression compared to the HFHC diet alone (P < 0.001) (Figure 3-13B). M2 gene
expression showed that liver Cd163 expression was significantly lower in HFHC-fed
mice compared to both the chow and 30 mg/kg BA groups. Expression of M2 genes Arg1
and Il10 were not different among groups in aorta and liver (Figure 3.14-A).
Additionally, Adgre1 expression, an estimation of total macrophage content, was
increased in the liver and aorta of HFHC-fed mice and was not further affected by BA
treatment (Figure 3-14A).
Chronic inflammation was assessed by measuring plasma Serum amyloid-A (SAA)
levels. This liver derived acute-phase protein is rapidly increased during exposure to
inflammatory stimuli and is also mildly elevated under conditions of low-grade chronic
inflammation (201, 202). After 12 weeks on diet, the change in plasma SAA
concentration from baseline was significantly greater in mice fed HFHC when compared
to mice fed chow (increase of 52% and 13%, respectively). Mice fed the HFHC diet also
had a significantly greater change in SAA concentrations compared to mice treated with
30 mg/kg BA (decrease of 19%) (Figure 3-15).
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Figure 3-9: Effects of BA on glycemia.
Fasting blood glucose (A) (n=24) and plasma insulin (B) (n=12) sampled every 4 weeks.
Data are means ± SEM, different letters indicate statistical differences of whole curves by
two-way ANOVA P < 0.05
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Figure 3-10: Effects of BA on glucose homeostasis.
Glucose tolerance test (GTT) (A) and incremental-GTT (iGTT) (B) with area under the
curve (AUC, inset) (n=12-15). Insulin tolerance test (ITT) (C) and iITT (D) with AUC
(inset) (n=19-20). Data are means ± SEM, different letters indicate statistical difference
by one-way ANOVA, P < 0.05.
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Figure 3-11: Effects of BA on hepatic inflammatory signaling pathways.
Representative immunoblots of biological replicates for mitogen-activated protein kinase
(MAPK) and nuclear factor-κB (NF-κB) pathway signaling (A) and quantitations by
densitometry shown below (B) (n=7-8). Data are means ± SEM, different letters indicate
statistical differences by one-way ANOVA, P <0.05.
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Figure 3-12: Effects of BA on aortic inflammatory signaling pathways.
Representative immunoblots of biological replicates for mitogen-activated protein kinase
(MAPK) and nuclear factor-κB (NF-κB) pathway signaling (A) and quantitations by
densitometry shown below (B) (n=5-8). Data are means ± SEM, different letters indicate
statistical differences by one-way ANOVA, P <0.05.
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Figure 3-13: Effects of BA on M1 inflammatory gene expression.
Hepatic M1 gene expression (n=11-12) (A). Full-length aortic M1 gene expression (n=58) (B). Data are means ± SEM, different letters indicated statistically significant
differences by one-way ANOVA, P < 0.05.
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Figure 3-14: Effects of BA on M2 gene expression.
Hepatic M2 gene expression arginase 1 (Arg1) and cluster of differentiation 163 (Cd163)
(n=11-12) (A). Full-length aortic M2 gene expression Arg1, Interleukin 10 (Il10), and
Cd163 (n=5-8) (B). (C) Hepatic and aortic adhesion G protein-coupled receptor E1
(Adgre1) (macrophage) gene expression (n=6-12). Data are means ± SEM, different
letters indicated statistically significant differences by one-way ANOVA, P < 0.05.
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Figure 3-15: Effects of BA on chronic inflammation.
Percent change in plasma concentration of serum amyloid-A (SAA) from baseline to 12
weeks on diet (n=10-16). Data are means ± SEM, different letters indicated statistically
significant differences by one-way ANOVA, P < 0.05.
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3.8
Bempedoic acid prevents atherosclerotic lesion
development
The aortic sinus was sectioned for histological examination of atherosclerotic lesion
development and morphology. Lesion analysis of H&E or ORO stained sections of the
aortic sinus revealed the development of small fatty streaks in chow-fed mice, whereas
the lesions in HFHC-fed mice were significantly larger by 16-fold (Figure 3-16).
Compared with HFHC-fed mice, treatment with 30 mg/kg BA robustly attenuated lesion
size (-47%) as measured by lesion area stained with ORO (Figure 3-16). Lipid analysis of
whole aortae revealed that TC and CE increased significantly in mice fed the HFHC diet,
as compared to chow-fed mice, and CE was decreased significantly by treatment with 10
and 30 mg/kg BA. There was a trend to increased aortic FC and TG with the HFHC-diet
and a trend to lower FC and TG values in mice treated with BA at 10 and 30 mg/kg
(Figure 3-17). Lesion morphology was further analyzed by immunohistochemistry (IHC)
using macrophage and smooth muscle cell-specific antibodies (CD68 and α-actin,
respectively) and by Picrosirius Red staining for collagen content. Chow-fed mice were
not included in further lesion analysis due to their small lesion size (Figure 3-16). In 30
mg/kg BA-treated mice, macrophage content as a percent of lesion area was significantly
greater than in lesions from HFHC-fed mice, while percent smooth muscle α-actin was
nonsignificantly lower (Figure 3-18). Total collagen content was unchanged between the
HFHC and 30 mg/kg groups. Levels of lesion apoptosis, measured by percent of
activated caspase-3 positive nuclei, were significantly lower with 30 mg/kg BA treatment
compared to mice fed HFHC alone (Figure 3-19). Collectively, this suggests that in
addition to smaller lesion size, BA-treated mice have more macrophages, fewer SMCs,
and fewer apoptotic cells per lesion, consistent with earlier stage lesions. Collectively,
this implies that BA suppresses the development of atherosclerosis in this model.
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Figure 3-16: Effects of BA on atherosclerotic lesion development.
Representative images of H&E or ORO stained aortic sinus sections (A). Quantitation of
lesion area from ORO images (B) (n=10-13). Data are means ± SEM, different letters
indicate statistical differences by one-way ANOVA, P <0.05.
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Figure 3-17: Effects of BA on aortic lipid accumulation.
Aortic free cholesterol (FC), cholesteryl ester (CE), total cholesterol (TC), and
triacylglycerol (TG) content (n=11-12). Data are means ± SEM, different letters indicate
statistical differences by one-way ANOVA, P <0.05.
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Figure 3-18: Effects of BA on atherosclerotic lesion morphology.
Representative immunohistochemistry stains for CD68, smooth muscle (SM) α-actin and
Picrosirius Red (A) with quantitation shown below (B) (n=8-13). Chow mice were not
included in the analysis due to very small lesion size (see Figure 3-16). Data are means ±
SEM, different letters indicate statistical differences by unpaired two-tailed t test, P-value
shown on graph.
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Figure 3-19: Effects of BA on atherosclerotic lesion apoptosis.
Representative immunohistochemistry stains of cleaved caspase-3 with quantitation of
proportion of positively stained nuclei shown on right (n=4-5). Chow mice were not
included in the analysis due to very small lesion size (see Figure 3-16). Data are means ±
SEM, different letters indicate statistical differences by unpaired two-tailed t test, P-value
shown on graph.
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Chapter 4

4

Discussion

CVD risk management has improved tremendously over the past few decades. However,
CVD continues to be a major cause of death in developed countries, driven in part by the
rapidly increasing prevalence of the metabolic syndrome and Type 2 Diabetes mellitus.
Strong evidence from large-scale clinical trials support the notion that lowering LDL-C
reduces CVD risk. Statins have shown proven efficacy in lowering LDL-C and
preventing CVD events but despite this, many at-risk patients are unable to reach their
target LDL-C levels leaving a large group of individuals with significant residual risk. As
a result, novel therapeutic options are needed to treat cardiometabolic risk factors.
One significant barrier to managing lipid levels is the often overlooked condition referred
to as statin intolerance. This has typically lacked a consensus definition and the reported
prevalence rates can range from 7-29% (203). However, it appears to be gaining
increasing attention from the medical community. Statin intolerance can be loosely
defined as when a patient is unable to take a statin due to any number of side effects, thus
preventing them from achieving their target LDL-C goal (204, 205). Of course, this is a
major cause for concern due to the increased CVD risk seen with statin noncompliance
and failure to reach target LDL-C goals (206, 207). Side effects most commonly include
discomfort from the myopathy-associated muscle pain, along with a small risk for new
onset of Type 2 Diabetes or a rise in liver function enzymes (205). While these don’t
negate the CVD benefit seen with statins, it still has a great impact on patient quality of
life and can reduce compliance.
Mechanistically, it is thought that the muscle side effects of statins are a result of the drug
acting directly on muscle tissue (208). Within the skeletal muscle, myocyte dysfunction
and damage has been suggested to be caused by myocyte HMG-CoA reductase inhibition
and the resulting lowering of myocyte cholesterol synthesis (209) or off-target effects
within muscle tissues by statins themselves (210). This myocyte damage can present as
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muscle pain and myopathy, and perhaps even reduce glucose utilization by muscle,
increasing blood glucose levels and Type 2 Diabetes risk.
Bempedoic acid (BA, also known as ETC-1002) is in clinical development for the
treatment of hypercholesterolemia in patients at a high risk for CVD (details of BA,
including mechanism of action, are reviewed in section 1.7.6.1). In up to phase IIb
clinical trials, BA has consistently demonstrated LDL-C lowering of up to 30% as
monotherapy (171), 50% as an add-on to ezetimibe therapy (174), and 24% as an add-on
to statin therapy (175). Whether or not this translates into protection from CVD is not
known.
The current study was undertaken to address the question of whether or not BA could
prevent the development of atherosclerosis in Ldlr-/- mice fed a HFHC diet, along with
other components of the metabolic syndrome such as obesity, dyslipidemia, insulin
resistance, and chronic inflammation. Mice were randomized to receive a chow diet, a
HFHC diet, or BA added to the HFHC diet at the doses of 3, 10, or 30 mg/kg. In most
cases, the metabolic abnormalities assessed were reduced with the dose of 30 mg/kg BA
over a 12-week period. For example, when compared to mice fed the HFHC diet alone,
mice treated with 30 mg/kg BA showed reduced body weight and adiposity, reduced
lipids in the plasma, liver, and aorta, improved glycemia, reduced chronic inflammation,
and reduced atherosclerotic burden. This effect was often mirrored in mice receiving 10
mg/kg BA for several, but not all parameters measured. Mice receiving the lowest dose of
3 mg/kg showed little difference compared to mice receiving HFHC alone for almost all
the parameters measured. One exception was plasma TG concentration where 3 mg/kg
BA significantly lowered plasma TG compared to HFHC, with similar efficacy seen with
the higher two doses of BA. BA at 30 mg/kg was effective in preventing atherosclerosis
in Ldlr-/- mice fed a HFHC diet.

4.1 Interpretation and evaluation of results
4.1.1

Hyperlipidemia and tissue lipid accumulation

In terms of lipid-based parameters, mice responded as expected to receiving the HFHC
diet for 12 weeks. Using the Ldlr-/- mouse model in combination with the HFHC diet is a
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very reliable and robust model of lipid-induced atherosclerosis. The large increase in
dyslipidemia and atherosclerotic lesion size seen in the HFHC-fed mice attest to this.
Other lipid-related parameters also demonstrate this, as hepatic and aortic lipids, along
with adiposity and total body weight, are greatly elevated in mice when comparing
HFHC feeding to chow. The sheer magnitude of effect size exemplifies the strength of
this model for studying hyperlipidemia and other components of the metabolic syndrome
and atherosclerosis.
Overall, BA showed robust efficacy when it came to preventing the hyperlipidemia and
tissue lipid accumulation induced by the HFHC diet. Plasma cholesterol and TGs were
increased several fold in HFHC-fed mice compared to chow. Separation of plasma
lipoproteins by FPLC analysis revealed that this took place in the VLDL, IDL, and LDL
cholesterol fractions along with the VLDL TG fractions. 30 mg/kg BA attenuated
hypercholesterolemia primarily in the VLDL and possibly IDL fractions. 10 mg/kg BA
also significantly reduced plasma cholesterol, which appeared to take place in the VLDL
fraction but not to a great enough extent to reach statistical significance. 3 mg/kg did not
significantly lower plasma cholesterol concentrations compared to HFHC, as was the
case with most parameters measured. However, it was very interesting to observe that all
three doses of BA did elicit a statistically significant reduction in plasma TG. This was
unusual in that it was one of the only parameters for which the 3 mg/kg BA had a
statistically significant effect compared to the HFHC diet. FPLC analysis showed that
plasma TG reduction took place in the VLDL fractions, as most plasma TG is found here
in fasted mice. Although not measured directly, reductions in VLDL cholesterol and TG
by BA were likely a result of reduced hepatic lipoprotein production.

4.1.2

Glucose homeostasis

Other parameters showed a moderate but still significant response to the HFHC diet in
comparison to chow, although not to the same extent as observed with the lipid
measurements. Glucose homeostasis was generally worsened with HFHC feeding, as
shown by increased fasting glucose and insulin, GTTs, and ITTs. When data from the
tolerance tests were normalized to baseline glucose value, there was still a significant
difference in glucose sensitivity but there was no significant effect on insulin sensitivity.
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This can be interpreted a few different ways. Two important factors that need to be
considered when interpreting the data are the baseline differences in both body weight
and blood glucose. Differences in body weight will influence the dose of glucose or
insulin received. Additionally, increased weight is likely due to increased adiposity while
glucose disposal is primarily done by lean tissues, such as muscle, brain, and liver (211).
In the current study, mice fed the HFHC diet received far greater doses of glucose and
insulin due to their increased body weight. It is therefore possible that glucose tolerance
was similar between groups and the perceived glucose intolerance in the HFHC-fed mice
is the result of a larger dose of glucose. Alternatively, it has been suggested that mice
should receive glucose based on the weight of their lean tissue, not total body weight, if
such information is available (212). This can be determined by μCT scanning. Fixed
glucose dosing is also a possibility and has been demonstrated in chow versus high fat
fed mice (213). Additionally, baseline glucose values were not the same across the
treatment arms of the study. Therefore, comparisons of the absolute GTT and ITT data
would not be appropriate and data should be analyzed as glucose normalized to baseline
or baseline-subtracted glucose (211), as shown in Figure 3-10B and 3-10D.
When looking at fasting glucose values taken over the course of the study, an interesting
trend becomes apparent. Statistical analysis of the time course plots showed that mice in
the chow and 30 mg/kg BA groups had significantly lower fasting glucose values than the
HFHC and 3 and 10 mg/kg BA groups. It is stated in the results section that this is an
attenuation of hyperglycemia, but closer inspection of the graphs suggests that the HFHC
and lower dose BA groups had no change in glycemia while the chow and high dose BA
groups displayed a reduction in glycemia. A likely explanation is that at baseline, mouse
glucose values were slightly inflated due to a stress response from the tail bleed
procedure. In fact, it is known that mice will increase glucose production under
conditions of stress, likely through an increase in levels of catecholamines and cortisol
(214, 215). As the study progressed, mice became more acclimatized to the glucose
monitoring procedure so that by week 12, normoglycemic mice (chow and 30 mg/kg BA)
showed a reduction while hyperglycemic mice (HFHC and 3 and 10 mg/kg BA) show no
change in fasting blood glucose concentrations. If this scenario is true, then it would be
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valid to suggest that chow and 30 mg/kg BA groups are normoglycemic relative to the
other three groups which display hyperglycemia, as stated in section 3.6.

4.1.3

Metabolic measures

A number of metabolic measurements were taken including fatty acid β-oxidation, fatty
acid synthesis, and metabolic cage analyses such as oxygen utilization, and carbon
dioxide production. Fatty acid β-oxidation was measured using radiolabeled [3H]-palmitic
acid and tracking its conversion to deuterated water (3H2O). While most of this process
takes place in the mitochondria, peroxisomes are another potential site of β-oxidation and
both organelles contain similar enzymes but with different substrate specificities (216,
217). Specifically, all very-long-chained fatty acids (24-30 carbons) and some long-chain
fatty acids (12-22 carbons) undergo β-oxidation exclusively in peroxisomes, most longchain fatty acids and all medium-chain (6-12 carbons) and short-chain (<6 carbons) fatty
acids undergo β-oxidation in the mitochondria (218). Since BA treatment had a large
peroxisome proliferation effect, peroxisomal β-oxidation could account for much of the
increased fatty acid β-oxidation of long-chain and very-long chain fatty acids. While the
relative contribution of mitochondrial and peroxisomal β-oxidation was not determined,
this could be estimated by performing the β-oxidation assay with or without a CPT1α
inhibitor (such as etomoxir (219)). During inhibition of mitochondrial β-oxidation, the
remaining β-oxidation would likely be peroxisomal, although this theory has yet to be
validated.
Fatty acid synthesis was analyzed my measuring the incorporation of [1-14C]-acetic acid
into fatty acids. A very important consideration for using this method is the effect of
radiolabeled substrate dilution within the endogenous cytosolic acetyl-CoA pool (220–
224). Therefore, the assumption is made that acetyl-CoA pool sizes and thus radiolabel
dilutions are equal between groups. However, the current study employs a specific
inhibitor of acetyl-CoA synthesis and it is known that BA reduces intracellular acetylCoA concentrations (177), so these results should be interpreted cautiously. An
alternative approach is to use tritium-labeled water (3H2O) as its specific activity should
be similar between experimental groups (221). However, a major limitation of this
approach is the very high amounts of radioactivity necessary to perform assays using
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tritium-labeled water as substrate, especially when studying a large number of subjects
(221).
Metabolic cages were used to measure volume of oxygen utilized (VO2) and carbon
dioxide produced (VCO2). The analysis of murine energy expenditure has long been an
area of controversy and different means of data analysis can yield very different results
(225–231). It is common to find literature example of misinterpretations of data or
unsubstantiated conclusions (231). One of the greatest confounding factors of energy
metabolism in humans and mice is the role of body mass (225, 226). While it is known
that energy expenditure increases with body mass, this relationship is certainly not linear.
In models of diet-induced obesity, increased body mass is driven by increased adiposity.
While adipose tissue does contribute to energy expenditure, the effect is not as great as
the contribution from lean tissue. However, it is very common for investigators to
normalize energy expenditure to total body mass, thus in a model of diet-induced obesity
this will give the appearance of diminished energy expenditure in the obese group (225).
A better way to characterize energy expenditure when body weight differences are
present is to normalize the data to each mouse's lean body mass, which can be determined
by μCT or nuclear magnetic resonance imaging. A much more robust method involves
using analysis of covariance (ANCOVA), where energy expenditure is plotted in relation
to body weight or lean body weight for each individual mouse. Displaying the data this
way reveals if differences in energy expenditure are the result of different body weights,
or if the treatment has an effect compared to the control group (225, 226). Another
important consideration when doing energy expenditure analysis is that very subtle
changes in metabolic rates can have a significant effect over a long period of time (229).
Taking the current study as an example, a small reduction in body weight seen in BAtreated mice compared to HFHC-fed controls (~ 2 grams) occurred over the course of the
12-week study. Assuming this is 2 grams of pure fat, this would represent 74 kJ of energy
(2 x 37 kJ/gram fat) and thus a difference in energy expenditure of ~0.9 kJ per day over
the 12-week study. Assuming there are no differences in caloric intake between mice fed
the HFHC diet compared to BA-treated mice, and that an average mouse has an energy
expenditure of 50-60 kJ/day(231), BA-treated mice only need to expend < 2% more
energy to display the observed difference in body weight. Needless to say, such a small
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difference in daily energy expenditure is far less than what indirect calorimetry can
accurately detect (231).

4.1.4

Inflammation

The effects of BA on inflammation were assessed by measuring several markers of
inflammation in the liver, aorta, and plasma. The HFHC diet induces chronic, metabolic
inflammation, exacerbated by the addition of cholesterol. This effect is moderate, in
contrast to the large effect seen in acute inflammation, such as when lipopolysaccharide
(LPS) is administered to mice (232, 233). Analyses of inflammatory gene expression,
intracellular signaling pathways, and plasma markers were carried out to try and detect
the low grade inflammation seen with the HFHC diet and its resolution seen with BA
treatment.
The effects of the HFHC diet can be seen on hepatic and aortic inflammatory gene
expression in comparison to chow fed mice. One set of genes represents an M1
macrophage phenotype, which is indicative of classically activated, proinflammatory
macrophages. This is in contrast to M2 genes which represent alternatively activated,
reparative, anti-inflammatory macrophages. In liver there was a suppressive effect of the
HFHC diet on M2 gene expression, but not in aortae. Additionally, total macrophages
content was increased in the aortae and liver of mice fed the HFHC diet compared to
chow-fed mice, as measured by Emr1 gene expression. Overall, BA attenuated this
proinflammatory gene expression pattern. This was observed with 30 mg/kg BA-treated
mice for most hepatic proinflammatory genes measured. Additionally, hepatic Nos2/Arg1
was reduced in 30 mg/kg BA-treated mice compared to HFHC-fed mice, suggesting that
the population of macrophages present in the liver displayed more of an M2 phenotype.
In the aorta, BA at any dose did not significantly lower proinflammatory gene expression
but trends can be observed in the data for the 10 and 30 mg/kg doses. Collectively,
comparing expression of all aortic M1 genes between groups fed the HFHC diet +/- BA
by two-way ANOVA revealed a significant effect of BA compared to HFHC-feeding
alone (P < 0.0001). The lack of any statistically significant effect in the aorta on any
individual gene is likely attributable to an insufficient sample size for these relatively low
abundance mRNAs. Chow-fed mice showed relatively constant aortic M1 gene
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expression while in HFHC-fed mice, expression was highly variable. The intermediate
M1 gene expression seen in BA-treated mice was also highly variable. With this high
standard deviation and a total 5 treatment groups, a much greater sample size would have
been needed to detect statistically significant effects of BA on aortic inflammation.
Intracellular inflammatory signaling was also assessed by immunoblotting for
phosphorylated MAPK and NF-κB pathway proteins. Overall there was a limited effect
of the diet on the phosphorylation of these proteins, and in many instances there was no
difference between chow and HFHC-fed mice. This was unexpected since the
inflammatory gene expression data did show an effect of the HFHC diet. 30 mg/kg BA
treated mice showed reduced phosphorylation of hepatic ERK and p38 and aortic JNK,
compared to HFHC fed mice while other MAPK proteins and none of the NF-κB proteins
showed any differences. A likely explanation is that the chronic low-grade inflammation
seen with in HFHC fed mice has a very subtle effect on phosphorylation of MAPK and
NF-κB proteins, below what phosphoprotein immunoblotting could accurately detect.
This small effect size combined with the small sample size (8 or less) likely explains the
limited differences seen in inflammatory signaling pathway phosphorylation.
A third marker of inflammation was performed by measuring plasma concentrations of
the SAA protein. This acute-phase protein is rapidly secreted by the liver in response to
inflammatory stimuli. Additionally, it is modestly elevated under conditions of chronic
inflammation. Unexpectedly, several mice exhibited very large increases in SAA
concentration (100-fold greater than group mean) independent of treatment group and
study time point. In these cases, mice consistently exhibited signs of aggression and
dominance behavior, occasionally having visible wounds. This is not atypical mouse
behavior, especially among male mice and other investigators have made similar
observations (234, 235). These mice were excluded and in the remaining mice the change
in SAA from baseline to week 12 was analyzed. Mice fed chow showed little change in
SAA concentration while in mice fed the HFHC diet plasma SAA was increased by
approximately 50%. This was prevented in mice treated with 30 mg/kg BA and their
SAA concentrations actually showed a slight decrease from baseline. This is likely owing
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to the known anti-inflammatory properties of BA, as demonstrated by the CRP lowering
seen in clinical trials.

4.1.5

Atherosclerosis

As mentioned in section 4.1.1, the Ldlr-/- mouse is a good model of atherosclerosis due
to the severity of dyslipidemia that develops in response to the HFHC diet. As expected,
the HFHC-fed mice developed very large lipid and foam cell-rich lesions within the
aortic roots, while lesions in chow-fed animals were barely detectable. 30 mg/kg BA
showed a robust reduction in lesion size compared to HFHC-fed mice an effect which
was comparable to the degree of plasma cholesterol lowering. Further analyses were
performed to study lesion composition and morphology. In addition to a reduced lesion
size, BA treated mice had a higher macrophage content, slightly lower smooth muscle
cell contents, and a reduced percentage of apoptotic cells, all indicative of a less
advanced stage lesion.

4.2 The question of mechanism
Overall, these findings are consistent with BA inhibiting hepatic ACL and activating
AMPK. Additionally, BA appeared to stimulate PPARα activation which offers a third
mechanistic explanation of the results. The current study was not designed to determine a
specific mechanism(s). However, comparing the data from BA-treated mice with
literature data may offer insight into the relative contributions of the three potential
mechanisms.

4.2.1

Comparison to related drugs and mouse models

Many previous studies have looked at genetic knockouts, overexpression, or chemical
inhibition or activation of AMPK, ACL, PPARα, or closely related pathways in mouse
models of metabolic disease. These studies can be helpful when interpreting the data
from the current study.
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4.2.1.1.1

AMPK

Activation of AMPK under conditions of low intracellular energy results in an
upregulation of catabolic, ATP-producing pathways and an inhibition of anabolic, ATPconsuming pathways (See section 1.7.5). Therefore, it is thought to be a promising drug
target for the treatment of metabolic diseases. Most AMPK activators work via inhibition
of the mitochondria respiratory chain, thus increasing cellular AMP levels and AMPK
activation (236). Therefore, these are indirect activators and are not specific for AMPK.
BA has been shown to activate AMPK without altering adenylate nucleotide levels (177),
decreasing the likelihood of an AMP-mediated mechanism of AMPK activation.
Resveratrol and other polyphenols are good examples of indirect AMPK activators that
have been very well studied. While the mechanisms of polyphenols are complex and
controversial (237) their cardioprotective potential has been demonstrated in several
animal models (238–241). For example, the synthetic polyphenol S17834 has been
shown to activate AMPK while inhibiting diet-induced hepatic steatosis, hyperlipidemia,
and atherosclerosis in Ldlr-/- mice (240). These effects are thought to involve AMPKmediated inhibition of SREBPs (242). Specifically, S17834 was shown to reduce hepatic
expression of SREBP-2 and its target genes (242). In contrast, BA appeared to increase
SREBP-2 target gene expression, which may be a feedback effect from cholesterol
synthesis inhibition.
While compounds that activate AMPK indirectly have been well studied, direct AMPK
activators have only been characterized relatively recently. Compound A-769662 was
developed by Abbott Laboratories and was the first described direct AMPK activator
(243). It was demonstrated to activate AMPK independently of upstream kinases (244)
and cellular AMP levels (245) in a manner requiring the β-subunit of AMPK (245, 246).
Additionally, A-769662 preferentially activated β1-containing complexes over β2 (246).
In leptin-deficient (ob/ob) mice, a model of diet-induced obesity, A-769662 was effective
in reducing plasma glucose, body weight, and plasma and liver TG, but displayed poor
bioavailability (243). Salicylate was also found to bind the same β1-subunit site as A769662 and had similar effects (154). Although it has better bioavailability, its effects on
atherosclerosis are not yet known. Based on this information and the similar metabolic
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effects observed with BA, it would be interesting to test if BA has similar AMPK β1subunit binding properties.
Two additional compounds known as 991 (247) (also known as ex229 (248)) and MT 6378 (249) have been recently developed and also show preference towards the AMPK β1subunit (236). Compound C13 (and its metabolite C2) has been shown to directly target
α1-containing AMPK complexes (250, 251). Lastly, CNX-012-570 has been shown to
directly activate γ-containing subunits (252). Collectively, these direct activators have
only been characterized very recently and several key aspects such as bioavailability and
toxicology profile have not been described. It is difficult to make comparisons of these
compounds with BA, until further information on these compounds are published.
Therefore, while AMPK activation can certainly be observed with BA treatment (177,
178) the contributing role of AMPK activation in BA’s mechanism of action remains
undetermined.

4.2.1.1.2

ACL

Besides BA, other inhibitors of ACL have been tested but none are currently in clinical
development. Prior examples of ACL inhibitors include hydroxycitrate, a natural
inhibitor (253–256), and the synthetic inhibitors BMS-303141 (257–259) and SB-204990
(260–262). However common issues with these compounds include poor membrane
permeability and the high doses required to elicit an effect, resulting in off-target effects
(170, 253, 263).
Previous studies of in vivo inhibition of ACL have reported very similar effects as seen
with BA treatment. For example, treatment of rats with hydroxycitrate inhibited hepatic
cholesterol and fatty acid synthesis (254–256, 264). Treatment of rats with SB-204990
reduced plasma cholesterol and TG (262) while treatment of high-fat fed mice with
BMS-303141 reduced plasma lipids, glucose, and body weight gain (259).
Of particular interest are studies where ACL knockdown was performed specifically in
the liver. Wang, et al. demonstrated that in leptin receptor-deficient (db/db) mice this
reduced hepatic levels of acetyl-CoA, malonyl-CoA, lipogenesis, and TG while also
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improving fasting glucose, and glucose tolerance (165). Interestingly, hepatic gene
expression analysis revealed a small increase in SREBP-2 expression similar to what was
seen with BA. However, expression of ACC and FAS were suppressed in the ACL
deficient mice, in contrast to what was seen with BA in the current study. Additionally,
ACL deficient mice showed a marked suppression of Ppara and Acox expression (165),
in contrast to the large induction seen with BA treatment. This is likely owing to the fact
that in the current study, BA treatment in mice likely inhibited ACL and activating
PPARα while the study by Wang, et al. looked a hepatic ACL deficiency alone (165). A
follow up study examined hepatic ACL knockdown in wild type mice fed either a low- or
high-fat diet (166). Again, ACL knockdown reduced hepatic acetyl-CoA, malonyl-CoA
and plasma TG on both diets, and while hepatic VLDL TG secretion was also reduced,
hepatic TG was actually increased (166). The latter result is difficult to reconcile with all
the other findings, and it is important to note that different diets and mouse models can
sometimes produce very different effects. Overall, however, these examples are mostly
consistent with the notion that the effects of BA in the current study are largely mediated
by hepatic ACL inhibition.

4.2.1.1.3

PPARα

Peroxisome proliferator-activated receptor α (PPARα) is a transcriptional regulator of
genes involved in lipid and lipoprotein metabolism, with a significant effect on regulating
β-oxidation (265). It is the target of most fibrates, a class of drugs in clinical use as an
add-on therapy for hyperlipidemia (265, 266). PPARα has been best studied for its role in
the liver but it is also highly expressed in heart, kidney, and muscle (267–269). In the
current study, there is a clear peroxisome proliferation effect of BA on murine liver,
possible due to PPARα activation.
The effects of fibrates in mouse models of cardiovascular disease have been mixed. The
fibrate ciprofibrate was shown to increase plasma cholesterol and atherosclerosis in
Apoe-/- mice (270) and Ldlr-/- mice (271). Fenofibrate was also shown to increase
plasma cholesterol but have no effect on atherosclerosis in Apoe-/- mice (272, 273) while
conversely reducing plasma lipids and atherosclerosis in Ldlr-/- mice (274). Gemfibrozil
decreased cholesterol and atherosclerosis in Apoe-/- mice (275, 276). Bezafibrate
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decreased cholesterol and atherosclerosis in Ldlr-/- mice (277). Clearly there is difficulty
in interpreting this data. However, if one looks at only the studies in Ldlr-/- mice where
fenofibrate and bezafibrate were shown to reduce atherosclerosis, the data is very similar
to the results of BA treatment in the current study. For example, similar to BA, fibrate
treatment reduced body weight, fat pad mass, plasma cholesterol and TG, and
atherosclerosis, while also increasing Aco gene expression (274, 277).
An important thing to note about PPARα agonists is that rodent models are highly
sensitive to peroxisome proliferators. Even under short exposure to fibrates, rodents will
display large increases in liver weight due to both hyperplasia and hypertrophy (278).
This is precisely what was observed with BA treatment. Furthermore, under chronic
exposure of peroxisome proliferators rodents will display an increased incidence of
hepatocellular carcinoma (278, 279). It should be noted however, that this effect has not
been observed in humans or primates and for several decades fibrates have been in
clinical use for hypertriglyceridemia (279–281). Additionally, BA has successfully
completed long-term carcinogenicity and toxicology studies in rats and mice as required
by the Food and Drug Administration (282, 283).
In the current study, the large increase in fatty acid synthase (Fasn) gene expression seen
with BA treatment could further play a role in PPARα activation. The Semenkovich lab
previously demonstrated that knockout of Fasn in the liver of mice unexpectedly resulted
in fasting hypoglycemia, hepatic steatosis, and other phenotypes similar to that seen in
Ppara knockout mice (284). This suggested that FAS synthesizes an endogenous ligand
for PPARα, which the group showed in a later study (285). These studies demonstrated a
greater role for FAS beyond the storage of excess nutrients as fat. It appears that FAS can
work though signaling mechanisms to impact liver physiology (286). Therefore, it is
entirely possible that the large increase in Fasn expression seen with BA treatment could
be at least in part responsible for the increased PPARα activation.
In summary, the metabolic benefits seen with BA appear similar to some (but not all)
findings from studies of fibrates in mice. The strongest evidences for the involvement of
PPARα in the mechanism of action of BA are both the large increase in hepatic Aco gene
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expression and the increase in total liver mass. Authors of a previous study made very
similar observations (including a lack of increased hepatic Ppara expression), leading
them to suggest a mechanism that involves PPARα activation (287). Additionally,
increase fatty acid synthase activity (although not measured directly) could contribute to
this PPARα effect.

4.2.2

Comparison to clinical data

It is difficult to fully know the clinical implications of a drug based solely on data from
animal models. The discussion of PPARα and fibrates in the previous section exemplifies
this as studies in rodents inconsistently demonstrate a benefit with fibrates, while also
revealing side effects that appear to be clinically irrelevant. The current study
demonstrated that in Ldlr-/- mice fed a HFHC diet, BA can lower TG and cholesterol in
the plasma, liver, and aorta, increase hepatic lipid metabolism, improve glucose
homeostasis, lower markers of inflammation, and reduce atherosclerosis. These data
suggest a mechanism of action that very likely involves the inhibition of ACL, with a
possible contribution of AMPK activation, and certain involvement of PPARα activation
(based on increased liver size and Aco expression). In comparison, human trials with BA
have demonstrated robust efficacy in lowering LDL-C, non-HDL-C, apoB, and hsCRP
with limited effects on plasma TG, glycemia, blood pressure, and body weight. The lack
of any clinically significant effects on plasma TG in particular suggests that the human
mechanism does not involve PPARα activation. Collectively, the published literature on
the use of BA in clinical trials strongly suggests that in humans, BA’s primary
mechanism of action in humans is the inhibition of hepatic ACL, a limited but
undetermined effect of AMPK activation, and no effect on PPARα activation.

4.3 Conclusions
The results from this study demonstrate the clear efficacy of BA in preventing
atherosclerosis and other aspects of the metabolic syndrome in Ldlr-/- mice fed a HFHC
diet. Future studies should further expand both the current understanding of BA’s
mechanism of action while also determining if there any side effects or additional
benefits of chronic BA treatment. It remains to be determined what the contributions are
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of ACL, AMPK, and PPARα in BA’s metabolic effects. This can be explored using
knockout mice where each of these proteins are deleted in a whole-body, or preferably, a
liver-specific manner. Additionally, to determine the effects of BA on inflammation,
better in vivo inflammatory models could be utilized. As discussed already, using mice
receiving a large inflammatory stimulus would be superior to the chronic inflammation
seen in obesity for testing BA’s potentially anti-inflammatory effects. One additional
question that remains to be answered is whether or not BA has any lipid-independent
effects. Utilizing the inflammatory model just mentioned with acute BA treatment could
help answer this question, especially if any effects of BA on inflammation can be
detected prior to any changes in hepatic or plasma lipid levels.
In addition to further preclinical research, there remains much work to be done in human
clinical trials which are already well underway. Moving forward, it will be very
interesting to see how BA performs in future and ongoing clinical trials. Currently,
patient enrollment has begun for two additional trials. First, a Phase 2b trail will look at
the effects of BA when added to a high-dose (80 mg) of atorvastatin (NCT02659397).
And next, a Phase 3 trial will look at the long-term safety and tolerability of BA in highrisk patients with hyperlipidemia and high CVD risk (NCT02666664). Results from these
studies are eagerly anticipated.

110

References
1. Grundy, S. M. 2012. Pre-Diabetes, Metabolic Syndrome, and Cardiovascular Risk. J
Am Coll Cardiol. 59: 635–643.
2. Shulman, G. I. 2014. Ectopic fat in insulin resistance, dyslipidemia, and
cardiometabolic disease. New England Journal of Medicine. 371: 1131–41.
3. Fordyce, C. B., M. T. Roe, T. Ahmad, P. Libby, J. S. Borer, W. R. Hiatt, M. R.
Bristow, M. Packer, S. M. Wasserman, N. Braunstein, B. Pitt, D. L. DeMets,
K. Cooper-Arnold, P. W. Armstrong, S. D. Berkowitz, R. Scott, J. Prats, Z.
S. Galis, N. Stockbridge, E. D. Peterson, and R. M. Califf. 2015.
Cardiovascular Drug Development: Is it Dead or Just Hibernating? J. Am.
Coll. Cardiol. 65: 1567–1582.
4. Goldstein, J. L., and M. S. Brown. 2015. A Century of Cholesterol and Coronaries:
From Plaques to Genes to Statins. Cell. 161: 161–172.
5. Libby, P. 2013. Mechanisms of Acute Coronary Syndromes and Their Implications for
Therapy. New England Journal of Medicine. 368: 2004–2013.
6. Goldstein, J. L., and M. S. Brown. 2009. The LDL Receptor. Arterioscler Thromb
Vasc Biol. 29: 431–438.
7. Watson, H. 2015. Biological membranes. Essays In Biochemistry. 59: 43–69.
8. Boekholdt, S. M., G. K. Hovingh, S. Mora, B. J. Arsenault, P. Amarenco, T. R.
Pedersen, J. C. LaRosa, D. D. Waters, D. A. DeMicco, R. J. Simes, A. C.

111

Keech, D. Colquhoun, G. A. Hitman, D. J. Betteridge, M. B. Clearfield, J. R.
Downs, H. M. Colhoun, A. M. Gotto, P. M. Ridker, S. M. Grundy, and J. J.
P. Kastelein. 2014. Very low levels of atherogenic lipoproteins and the risk
for cardiovascular events: a meta-analysis of statin trials. J. Am. Coll.
Cardiol. 64: 485–494.
9. Anderson, T. J., J. Grégoire, R. A. Hegele, P. Couture, G. B. J. Mancini, R.
McPherson, G. A. Francis, P. Poirier, D. C. Lau, S. Grover, J. Genest Jr, A.
C. Carpentier, R. Dufour, M. Gupta, R. Ward, L. A. Leiter, E. Lonn, D. S.
Ng, G. J. Pearson, G. M. Yates, J. A. Stone, and E. Ur. 2013. 2012 Update of
the Canadian Cardiovascular Society Guidelines for the Diagnosis and
Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in
the Adult. Canadian Journal of Cardiology. 29: 151–167.
10. Hegele, R. A., S. S. Gidding, H. N. Ginsberg, R. McPherson, F. J. Raal, D. J. Rader,
J. G. Robinson, and F. K. Welty. 2015. Nonstatin Low-Density Lipoprotein–
Lowering Therapy and Cardiovascular Risk Reduction—Statement From
ATVB Council. Arterioscler Thromb Vasc Biol. ATVBAHA.115.306442.
11. Ray, K. K., J. J. P. Kastelein, S. M. Boekholdt, S. J. Nicholls, K.-T. Khaw, C. M.
Ballantyne, A. L. Catapano, Ž. Reiner, and T. F. Lüscher. 2014. The
ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce
atherosclerotic cardiovascular disease risk in adults: the good the bad and the
uncertain: a comparison with ESC/EAS guidelines for the management of
dyslipidaemias 2011. European Heart Journal. ehu107.

112

12. Wiegman, A., S. S. Gidding, G. F. Watts, M. J. Chapman, H. N. Ginsberg, M.
Cuchel, L. Ose, M. Averna, C. Boileau, J. Borén, E. Bruckert, A. L.
Catapano, J. C. Defesche, O. S. Descamps, R. A. Hegele, G. K. Hovingh, S.
E. Humphries, P. T. Kovanen, J. A. Kuivenhoven, L. Masana, B. G.
Nordestgaard, P. Pajukanta, K. G. Parhofer, F. J. Raal, K. K. Ray, R. D.
Santos, A. F. H. Stalenhoef, E. Steinhagen-Thiessen, E. S. Stroes, M.-R.
Taskinen, A. Tybjærg-Hansen, O. Wiklund, and European Atherosclerosis
Society Consensus Panel. 2015. Familial hypercholesterolaemia in children
and adolescents: gaining decades of life by optimizing detection and
treatment. Eur. Heart J. 36: 2425–2437.
13. Pownall, H. J., and A. M. Gotto Jr. 2016. New Insights into the High-Density
Lipoprotein Dilemma. Trends in Endocrinology & Metabolism. 27: 44–53.
14. Ramasamy, I. 2016. Update on the molecular biology of dyslipidemias. Clinica
Chimica Acta. 454: 143–185.
15. Grundy, S. M. 2016. Metabolic syndrome update. Trends in Cardiovascular
Medicine. 26: 364–373.
16. Taskinen, M.-R., and J. Borén. 2015. New insights into the pathophysiology of
dyslipidemia in type 2 diabetes. Atherosclerosis. 239: 483–495.
17. John Mancini, G. B., R. A. Hegele, and L. A. Leiter. 2013. Dyslipidemia. Canadian
Journal of Diabetes. 37, Supplement 1: S110–S116.

113

18. Twig, G., G. Yaniv, H. Levine, A. Leiba, N. Goldberger, E. Derazne, D. Ben-Ami
Shor, D. Tzur, A. Afek, A. Shamiss, Z. Haklai, and J. D. Kark. 2016. BodyMass Index in 2.3 Million Adolescents and Cardiovascular Death in
Adulthood. New England Journal of Medicine. 0: null.
19. Ärnlöv, J., E. Ingelsson, J. Sundström, and L. Lind. 2010. Impact of body mass index
and the metabolic syndrome on the risk of cardiovascular disease and death
in middle-aged men. Circulation. 121: 230–236.
20. Mottillo, S., K. B. Filion, J. Genest, L. Joseph, L. Pilote, P. Poirier, S. Rinfret, E. L.
Schiffrin, and M. J. Eisenberg. 2010. The metabolic syndrome and
cardiovascular risk: a systematic review and meta-analysis. Journal of the
American College of Cardiology. 56: 1113–1132.
21. Jacobson, T. A., M. K. Ito, K. C. Maki, C. E. Orringer, H. E. Bays, P. H. Jones, J. M.
McKenney, S. M. Grundy, E. A. Gill, R. A. Wild, D. P. Wilson, and W. V.
Brown. 2014. National Lipid Association recommendations for patientcentered management of dyslipidemia: Part 1 – executive summary. Journal
of Clinical Lipidology. 8: 473–488.
22. Ginsberg, H. N., and P. R. MacCallum. 2009. The obesity, metabolic syndrome, and
type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease
risk and the importance of atherogenic dyslipidemia in persons with the
metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr. 4:
113–119.

114

23. Wagenseil, J. E., and R. P. Mecham. 2009. Vascular Extracellular Matrix and Arterial
Mechanics. Physiological Reviews. 89: 957–989.
24. Libby, P., P. M. Ridker, and G. K. Hansson. 2011. Progress and challenges in
translating the biology of atherosclerosis. Nature. 473: 317–325.
25. Ponticos, M., and B. D. Smith. 2014. Extracellular matrix synthesis in vascular
disease: hypertension, and atherosclerosis. J Biomed Res. 28: 25–39.
26. Majesky, M. W., X. R. Dong, V. Hoglund, W. M. Mahoney, and G. Daum. 2011. The
Adventitia A Dynamic Interface Containing Resident Progenitor Cells.
Arterioscler Thromb Vasc Biol. 31: 1530–1539.
27. Cybulsky, M. I., C. Cheong, and C. S. Robbins. 2016. Macrophages and Dendritic
Cells Partners in Atherogenesis. Circ Res. 118: 637–652.
28. Brown, A. J., Z. Teng, P. C. Evans, J. H. Gillard, H. Samady, and M. R. Bennett.
2016. Role of biomechanical forces in the natural history of coronary
atherosclerosis. Nat Rev Cardiol. advance online publication. [online]
http://www.nature.com/nrcardio/journal/vaop/ncurrent/full/nrcardio.2015.20
3.html (Accessed March 13, 2016).
29. Hansson, G. K., P. Libby, and I. Tabas. 2015. Inflammation and plaque vulnerability.
J. Intern. Med.
30. Gimbrone, M. A., and G. García-Cardeña. 2016. Endothelial Cell Dysfunction and
the Pathobiology of Atherosclerosis. Circ Res. 118: 620–636.

115

31. Weber, C., and H. Noels. 2011. Atherosclerosis: current pathogenesis and therapeutic
options. Nat Med. 17: 1410–1422.
32. Shami, A., I. Gonçalves, and A. Hultgårdh-Nilsson. 2014. Collagen and related
extracellular matrix proteins in atherosclerotic plaque development. Curr.
Opin. Lipidol. 25: 394–399.
33. Dubland, J. A., and G. A. Francis. 2016. So Much Cholesterol: the unrecognized
importance of smooth muscle cells in atherosclerotic foam cell formation.
Curr. Opin. Lipidol. 27: 155–161.
34. Hutcheson, J. D., N. Maldonado, and E. Aikawa. 2014. Small entities with large
impact: microcalcifications and atherosclerotic plaque vulnerability. Curr.
Opin. Lipidol. 25: 327–332.
35. Bentzon, J. F., F. Otsuka, R. Virmani, and E. Falk. 2014. Mechanisms of Plaque
Formation and Rupture. Circ Res. 114: 1852–1866.
36. Insull, W. 2009. The Pathology of Atherosclerosis: Plaque Development and Plaque
Responses to Medical Treatment. The American Journal of Medicine. 122:
S3–S14.
37. Hegele, R. A. 2009. Plasma lipoproteins: genetic influences and clinical implications.
Nat. Rev. Genet. 10: 109–121.
38. Wasan, K. M., D. R. Brocks, S. D. Lee, K. Sachs-Barrable, and S. J. Thornton. 2008.
Impact of lipoproteins on the biological activity and disposition of

116

hydrophobic drugs: implications for drug discovery. Nat Rev Drug Discov.
7: 84–99.
39. Dash, S., C. Xiao, C. Morgantini, and G. F. Lewis. 2015. New Insights into the
Regulation of Chylomicron Production. Annual Review of Nutrition. 35:
265–294.
40. Xiao, C., S. Dash, C. Morgantini, and G. F. Lewis. 2014. New and emerging
regulators of intestinal lipoprotein secretion. Atherosclerosis. 233: 608–615.
41. Porter, C. J. H., N. L. Trevaskis, and W. N. Charman. 2007. Lipids and lipid-based
formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug
Discov. 6: 231–248.
42. White, C. R., D. I. Goldberg, and G. M. Anantharamaiah. 2015. Recent developments
in modulating atherogenic lipoproteins: Current Opinion in Lipidology. 26:
369–375.
43. Ramasamy, I. 2013. Recent advances in physiological lipoprotein metabolism.
Clinical Chemistry and Laboratory Medicine (CCLM). 52: 1695–1727.
44. Rye, K.-A., C. A. Bursill, G. Lambert, F. Tabet, and P. J. Barter. 2009. The
metabolism and anti-atherogenic properties of HDL. J. Lipid Res. 50: S195–
S200.
45. Kingwell, B. A., M. J. Chapman, A. Kontush, and N. E. Miller. 2014. HDL-targeted
therapies: progress, failures and future. Nat Rev Drug Discov. 13: 445–464.

117

46. Krauss, R. M. 2010. Lipoprotein subfractions and cardiovascular disease risk:
Current Opinion in Lipidology. 21: 305–311.
47. Pietrocola, F., L. Galluzzi, J. M. Bravo-San Pedro, F. Madeo, and G. Kroemer. 2015.
Acetyl Coenzyme A: A Central Metabolite and Second Messenger. Cell
Metabolism. 21: 805–821.
48. Platt, F. M., C. Wassif, A. Colaco, A. Dardis, E. Lloyd-Evans, B. Bembi, and F. D.
Porter. 2014. Disorders of Cholesterol Metabolism and Their Unanticipated
Convergent Mechanisms of Disease. Annual Review of Genomics and
Human Genetics. 15: 173–194.
49. Nes, W. D. 2011. Biosynthesis of Cholesterol and Other Sterols. Chem. Rev. 111:
6423–6451.
50. Perry, R. J., V. T. Samuel, K. F. Petersen, and G. I. Shulman. 2014. The role of
hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 510:
84–91.
51. Softic, S., D. E. Cohen, and C. R. Kahn. 2016. Role of Dietary Fructose and Hepatic
De Novo Lipogenesis in Fatty Liver Disease. Dig. Dis. Sci.
52. Horton, J. D., J. L. Goldstein, and M. S. Brown. 2002. SREBPs: activators of the
complete program of cholesterol and fatty acid synthesis in the liver. Journal
of Clinical Investigation. 109: 1125–31.

118

53. Brown, M. S., and J. L. Goldstein. 2009. Cholesterol feedback: from Schoenheimer’s
bottle to Scap’s MELADL. J. Lipid Res. 50: S15–S27.
54. Koliaki, C., and M. Roden. 2013. Hepatic energy metabolism in human diabetes
mellitus, obesity and non-alcoholic fatty liver disease. Molecular and
Cellular Endocrinology. 379: 35–42.
55. Begriche, K., J. Massart, M.-A. Robin, F. Bonnet, and B. Fromenty. 2013.
Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver
disease. Hepatology. 58: 1497–1507.
56. Rui, L. 2014. Energy Metabolism in the Liver. Compr Physiol. 4: 177–197.
57. Cherkaoui-Malki, M., S. Surapureddi, H. I. El-Hajj, J. Vamecq, and P. Andreoletti.
2012. Hepatic steatosis and peroxisomal fatty acid beta-oxidation. Curr.
Drug Metab. 13: 1412–1421.
58. Sassa, T., and A. Kihara. 2014. Metabolism of Very Long-Chain Fatty Acids: Genes
and Pathophysiology. Biomol Ther (Seoul). 22: 83–92.
59. Nakamura, M. T., B. E. Yudell, and J. J. Loor. 2014. Regulation of energy
metabolism by long-chain fatty acids. Progress in Lipid Research. 53: 124–
144.
60. Samuel, V. T., and G. I. Shulman. 2016. The pathogenesis of insulin resistance:
integrating signaling pathways and substrate flux. J. Clin. Invest. 126: 12–
22.

119

61. Xu, E., M. Schwab, and A. Marette. 2014. Role of protein tyrosine phosphatases in
the modulation of insulin signaling and their implication in the pathogenesis
of obesity-linked insulin resistance. Reviews in endocrine and metabolic
disorders. 15: 79–97.
62. Perry, R. J., J.-P. G. Camporez, R. Kursawe, P. M. Titchenell, D. Zhang, C. J. Perry,
M. J. Jurczak, A. Abudukadier, M. S. Han, X.-M. Zhang, H.-B. Ruan, X.
Yang, S. Caprio, S. M. Kaech, H. S. Sul, M. J. Birnbaum, R. J. Davis, G. W.
Cline, K. F. Petersen, and G. I. Shulman. 2015. Hepatic Acetyl CoA Links
Adipose Tissue Inflammation to Hepatic Insulin Resistance and Type 2
Diabetes. Cell.
63. Taniguchi, C. M., B. Emanuelli, and C. R. Kahn. 2006. Critical nodes in signalling
pathways: insights into insulin action. Nat Rev Mol Cell Biol. 7: 85–96.
64. Wu, X., K. Chen, and K. J. Williams. 2012. The role of pathway-selective insulin
resistance and responsiveness in diabetic dyslipoproteinemia. Current
Opinion in Lipidology. 23: 334–344.
65. Haas, M. E., A. D. Attie, and S. B. Biddinger. 2013. The regulation of ApoB
metabolism by insulin. Trends in Endocrinology & Metabolism. 24: 391–
397.
66. Choi, S. H., and H. N. Ginsberg. 2011. Increased very low density lipoprotein
(VLDL) secretion, hepatic steatosis, and insulin resistance. Trends in
Endocrinology & Metabolism. 22: 353–363.

120

67. Birkenfeld, A. L., and G. I. Shulman. 2014. Nonalcoholic fatty liver disease, hepatic
insulin resistance, and type 2 Diabetes. Hepatology. 59: 713–723.
68. Sparks, J. D., C. E. Sparks, and K. Adeli. 2012. Selective Hepatic Insulin Resistance,
VLDL Overproduction, and Hypertriglyceridemia. Arterioscler Thromb
Vasc Biol. 32: 2104–2112.
69. Brown, M. S., and J. L. Goldstein. 2008. Selective versus Total Insulin Resistance: A
Pathogenic Paradox. Cell Metabolism. 7: 95–96.
70. Könner, A. C., and J. C. Brüning. 2012. Selective Insulin and Leptin Resistance in
Metabolic Disorders. Cell Metabolism. 16: 144–152.
71. Laplante, M., and D. M. Sabatini. 2010. mTORC1 activates SREBP-1c and uncouples
lipogenesis from gluconeogenesis. Proc. Natl. Acad. Sci. U.S.A. 107: 3281–
3282.
72. Li, S., M. S. Brown, and J. L. Goldstein. 2010. Bifurcation of insulin signaling
pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but
not inhibition of gluconeogenesis. Proc. Natl. Acad. Sci. U.S.A. 107: 3441–
3446.
73. Holmes, D. 2015. Metabolism. Hepatic insulin resistance--missing link identified. Nat
Rev Endocrinol. 11: 193.

121

74. Otero, Y. F., J. M. Stafford, and O. P. McGuinness. 2014. Pathway-selective Insulin
Resistance and Metabolic Disease: The Importance of Nutrient Flux. J. Biol.
Chem. 289: 20462–20469.
75. Vatner, D. F., S. K. Majumdar, N. Kumashiro, M. C. Petersen, Y. Rahimi, A. K.
Gattu, M. Bears, J.-P. G. Camporez, G. W. Cline, M. J. Jurczak, V. T.
Samuel, and G. I. Shulman. 2015. Insulin-independent regulation of hepatic
triglyceride synthesis by fatty acids. Proc. Natl. Acad. Sci. U.S.A. 112:
1143–1148.
76. Malarkey, D. E., K. Johnson, L. Ryan, G. Boorman, and R. R. Maronpot. 2005. New
Insights into Functional Aspects of Liver Morphology. Toxicol Pathol. 33:
27–34.
77. Kelly, D. 2009. Diseases of the Liver and Biliary System in Children. John Wiley &
Sons.
78. Gordillo, M., T. Evans, and V. Gouon-Evans. 2015. Orchestrating liver development.
Development. 142: 2094–2108.
79. Chen, X.-M., S. P. O’Hara, and N. F. LaRusso. 2008. The immunobiology of
cholangiocytes. Immunol Cell Biol. 86: 497–505.
80. Jager, J., M. Aparicio-Vergara, and M. Aouadi. 2016. Liver innate immune cells and
insulin resistance: the multiple facets of Kupffer cells. J Intern Med. n/a-n/a.

122

81. Friedman, S. L. 2008. Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic
Cells of the Liver. Physiological Reviews. 88: 125–172.
82. Gruben, N., R. Shiri-Sverdlov, D. P. Y. Koonen, and M. H. Hofker. 2014.
Nonalcoholic fatty liver disease: A main driver of insulin resistance or a
dangerous liaison? Biochimica et Biophysica Acta (BBA) - Molecular Basis
of Disease. 1842: 2329–2343.
83. Asrih, M., and F. R. Jornayvaz. 2015. Metabolic syndrome and nonalcoholic fatty
liver disease: Is insulin resistance the link? Molecular and Cellular
Endocrinology. 418: 55–65.
84. Than, N. N., and P. N. Newsome. 2015. A concise review of non-alcoholic fatty liver
disease. Atherosclerosis. 239: 192–202.
85. Machado, M. V., and H. Cortez-Pinto. 2013. Non-invasive diagnosis of non-alcoholic
fatty liver disease. A critical appraisal. Journal of Hepatology. 58: 1007–
1019.
86. Pacana, T., and A. J. Sanyal. 2015. Recent advances in understanding/management of
non-alcoholic steatohepatitis. F1000Prime Rep. 7: 28.
87. Afdhal, N. H. 2012. Fibroscan (Transient Elastography) for the Measurement of Liver
Fibrosis. Gastroenterol Hepatol (N Y). 8: 605–607.
88. Yeh, M. M., and E. M. Brunt. 2014. Pathological features of fatty liver disease.
Gastroenterology. 147: 754–764.

123

89. Hardy, T., F. Oakley, Q. M. Anstee, and C. P. Day. 2016. Nonalcoholic Fatty Liver
Disease: Pathogenesis and Disease Spectrum. Annual Review of Pathology:
Mechanisms of Disease. 11: null.
90. Byrne, C. D., and G. Targher. 2014. Ectopic fat, insulin resistance, and nonalcoholic
fatty liver disease: implications for cardiovascular disease. Arterioscler.
Thromb. Vasc. Biol. 34: 1155–1161.
91. Samuel, V. T., and G. I. Shulman. 2012. Mechanisms for insulin resistance: common
threads and missing links. Cell. 148: 852–871.
92. Johnson, A. M. F., A. Costanzo, M. G. Gareau, A. M. Armando, O. Quehenberger, J.
M. Jameson, and J. M. Olefsky. 2015. High fat diet causes depletion of
intestinal eosinophils associated with intestinal permeability. PLoS ONE. 10:
e0122195.
93. Kirpich, I. A., L. S. Marsano, and C. J. McClain. 2015. Gut–liver axis, nutrition, and
non-alcoholic fatty liver disease. Clinical Biochemistry. 48: 923–930.
94. Seki, E., and R. F. Schwabe. 2015. Hepatic inflammation and fibrosis: functional
links and key pathways. Hepatology. 61: 1066–1079.
95. Szabo, G., and J. Petrasek. 2015. Inflammasome activation and function in liver
disease. Nat Rev Gastroenterol Hepatol. 12: 387–400.
96. Hopkins, P. N. 2013. Molecular Biology of Atherosclerosis. Physiological Reviews.
93: 1317–1542.

124

97. Kyriakis, J. M., and J. Avruch. 2012. Mammalian MAPK Signal Transduction
Pathways Activated by Stress and Inflammation: A 10-Year Update.
Physiological Reviews. 92: 689–737.
98. Osborn, O., and J. M. Olefsky. 2012. The cellular and signaling networks linking the
immune system and metabolism in disease. Nat Med. 18: 363–374.
99. Lackey, D. E., and J. M. Olefsky. 2016. Regulation of metabolism by the innate
immune system. Nat Rev Endocrinol. 12: 15–28.
100. Monje, P., J. Hernández-Losa, R. J. Lyons, M. D. Castellone, and J. S. Gutkind.
2005. Regulation of the Transcriptional Activity of c-Fos by ERK A
NOVEL ROLE FOR THE PROLYL ISOMERASE PIN1. J. Biol. Chem.
280: 35081–35084.
101. de Nadal, E., G. Ammerer, and F. Posas. 2011. Controlling gene expression in
response to stress. Nat Rev Genet. 12: 833–845.
102. Czaja, M. J. 2010. JNK regulation of hepatic manifestations of the metabolic
syndrome. Trends in Endocrinology & Metabolism. 21: 707–713.
103. Verstrepen, L., T. Bekaert, T.-L. Chau, J. Tavernier, A. Chariot, and R. Beyaert.
2008. TLR-4, IL-1R and TNF-R signaling to NF-kappaB: variations on a
common theme. Cell. Mol. Life Sci. 65: 2964–2978.
104. Mogensen, T. H. 2009. Pathogen Recognition and Inflammatory Signaling in Innate
Immune Defenses. Clin Microbiol Rev. 22: 240–273.

125

105. Cao, X. 2016. Self-regulation and cross-regulation of pattern-recognition receptor
signalling in health and disease. Nat Rev Immunol. 16: 35–50.
106. TANTI, J.-F., F. Ceppo, J. Jager, and F. Berthou. 2013. Implication of inflammatory
signaling pathways in obesity-induced insulin resistance. Front. Endocrin. 3:
181.
107. Qian, C., J. Liu, and X. Cao. 2014. Innate signaling in the inflammatory immune
disorders. Cytokine & Growth Factor Reviews. 25: 731–738.
108. Morrison, D. K. 2012. MAP Kinase Pathways. Cold Spring Harb Perspect Biol. 4:
a011254.
109. Newton, K., and V. M. Dixit. 2012. Signaling in Innate Immunity and Inflammation.
Cold Spring Harb Perspect Biol. 4: a006049.
110. Martin, M. U., and H. Wesche. 2002. Summary and comparison of the signaling
mechanisms of the Toll/interleukin-1 receptor family. Biochimica et
Biophysica Acta (BBA) - Molecular Cell Research. 1592: 265–280.
111. Takeuchi, O., and S. Akira. 2010. Pattern Recognition Receptors and Inflammation.
Cell. 140: 805–820.
112. Goodall, J. C., C. Wu, Y. Zhang, L. McNeill, L. Ellis, V. Saudek, and J. S. H.
Gaston. 2010. Endoplasmic reticulum stress-induced transcription factor,
CHOP, is crucial for dendritic cell IL-23 expression. PNAS. 107: 17698–
17703.

126

113. DeZwaan-McCabe, D., J. D. Riordan, A. M. Arensdorf, M. S. Icardi, A. J. Dupuy,
and D. T. Rutkowski. 2013. The Stress-Regulated Transcription Factor
CHOP Promotes Hepatic Inflammatory Gene Expression, Fibrosis, and
Oncogenesis. PLOS Genet. 9: e1003937.
114. Baan, B., H. van Dam, G. C. M. van der Zon, J. A. Maassen, and D. M. Ouwens.
2006. The role of c-Jun N-terminal kinase, p38, and extracellular signalregulated kinase in insulin-induced Thr69 and Thr71 phosphorylation of
activating transcription factor 2. Mol. Endocrinol. 20: 1786–1795.
115. Chait, A., and R. H. Eckel. 2016. Lipids, Lipoproteins, and Cardiovascular Disease:
Clinical Pharmacology Now and in the Future. The Journal of Clinical
Endocrinology & Metabolism. jc.2015-3940.
116. Ginsberg, H. N. 2006. REVIEW: Efficacy and mechanisms of action of statins in the
treatment of diabetic dyslipidemia. The Journal of Clinical Endocrinology &
Metabolism. 91: 383–92.
117. Horton, J. D., J. C. Cohen, and H. H. Hobbs. 2007. Molecular biology of PCSK9: its
role in LDL metabolism. Trends in Biochemical Sciences. 32: 71–77.
118. Lagace, T. A., D. E. Curtis, R. Garuti, M. C. McNutt, S. W. Park, H. B. Prather, N.
N. Anderson, Y. K. Ho, R. E. Hammer, and J. D. Horton. 2006. Secreted
PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers
of parabiotic mice. Journal of Clinical Investigation. 116: 2995–3005.

127

119. Cohen, J. C., E. Boerwinkle, T. H. J. Mosley, and H. H. Hobbs. 2006. Sequence
Variations in PCSK9, Low LDL, and Protection against Coronary Heart
Disease. New England Journal of Medicine. 354: 1264–1272.
120. Press, O. U. 2016. CardioPulse ArticlesThe PCSK9 storyWhat have we learned so
far from the biology of PCSK9?Nabil G. Seidah PhDThe biology of PCSK9
inhibition: some unanswered questionsProfessor Ulrich Laufs MDThe
annual Northwestern Cardiovascular Young Investigators’ Forum in
ChicagoNorthwestern Cardiovascular Young Investigators’ Forum, 2015
Winners. European Heart Journal. 37: 1341–1352.
121. Lagace, T. A. 2014. PCSK9 and LDLR degradation: regulatory mechanisms in
circulation and in cells. Current Opinion in Lipidology. 25: 387–393.
122. Sabatine, M. S., R. P. Giugliano, S. D. Wiviott, F. J. Raal, D. J. Blom, J. Robinson,
C. M. Ballantyne, R. Somaratne, J. Legg, S. M. Wasserman, R. Scott, M. J.
Koren, E. A. Stein, and Open-Label Study of Long-Term Evaluation against
LDL Cholesterol (OSLER) Investigators. 2015. Efficacy and safety of
evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med.
372: 1500–1509.
123. Altmann, S. W., H. R. Davis, L. Zhu, X. Yao, L. M. Hoos, G. Tetzloff, S. P. N. Iyer,
M. Maguire, A. Golovko, M. Zeng, L. Wang, N. Murgolo, and M. P.
Graziano. 2004. Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal
Cholesterol Absorption. Science. 303: 1201–1204.

128

124. Gotto, A. M., and J. E. Moon. 2013. Pharmacotherapies for lipid modification:
beyond the statins. Nat Rev Cardiol. 10: 560–570.
125. Cannon, C. P., M. A. Blazing, R. P. Giugliano, A. McCagg, J. A. White, P. Theroux,
H. Darius, B. S. Lewis, T. O. Ophuis, J. W. Jukema, G. M. De Ferrari, W.
Ruzyllo, P. De Lucca, K. Im, E. A. Bohula, C. Reist, S. D. Wiviott, A. M.
Tershakovec, T. A. Musliner, E. Braunwald, and R. M. Califf. 2015.
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New
England Journal of Medicine. 372: 2387–2397.
126. Barter, P. J., M. Caulfield, M. Eriksson, S. M. Grundy, J. J. P. Kastelein, M.
Komajda, J. Lopez-Sendon, L. Mosca, J.-C. Tardif, D. D. Waters, C. L.
Shear, J. H. Revkin, K. A. Buhr, M. R. Fisher, A. R. Tall, B. Brewer, and
ILLUMINATE Investigators. 2007. Effects of torcetrapib in patients at high
risk for coronary events. N. Engl. J. Med. 357: 2109–2122.
127. Tall, A. R., L. Yvan-Charvet, and N. Wang. 2007. The Failure of Torcetrapib Was it
the Molecule or the Mechanism? Arterioscler Thromb Vasc Biol. 27: 257–
260.
128. Joy, T., and R. A. Hegele. 2009. The end of the road for CETP inhibitors after
torcetrapib?: Current Opinion in Cardiology. 24: 364–371.
129. Schwartz, G. G., A. G. Olsson, M. Abt, C. M. Ballantyne, P. J. Barter, J. Brumm, B.
R. Chaitman, I. M. Holme, D. Kallend, L. A. Leiter, E. Leitersdorf, J. J. V.
McMurray, H. Mundl, S. J. Nicholls, P. K. Shah, J.-C. Tardif, and R. S.

129

Wright. 2012. Effects of Dalcetrapib in Patients with a Recent Acute
Coronary Syndrome. New England Journal of Medicine. 367: 2089–2099.
130. A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol - Full
Text View - ClinicalTrials.gov. [online]
https://clinicaltrials.gov/ct2/show/NCT02227784?term=LY2484595&phase
=123&rank=3 (Accessed March 17, 2016).
131. Sheridan, C. 2016. CETP inhibitors boost “good” cholesterol to no avail. Nat
Biotech. 34: 5–6.
132. Barter, P. J., S. J. Nicholls, J. J. P. Kastelein, and K.-A. Rye. 2015. Is Cholesteryl
Ester Transfer Protein Inhibition an Effective Strategy to Reduce
Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce
Cardiovascular Risk: The Pro Case. Circulation. 132: 423–432.
133. Hovingh, G. K., K. K. Ray, and S. M. Boekholdt. 2015. Is Cholesteryl Ester
Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular
Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief?
Circulation. 132: 433–440.
134. Marotti, K. R., C. K. Castle, T. P. Boyle, A. H. Lin, R. W. Murray, and G. W.
Melchior. 1993. Severe atherosclerosis in transgenic mice expressing simian
cholesteryl ester transfer protein. Nature. 364: 73–75.
135. Plump, A. S., L. Masucci-Magoulas, C. Bruce, C. L. Bisgaier, J. L. Breslow, and A.
R. Tall. 1999. Increased atherosclerosis in ApoE and LDL receptor gene

130

knock-out mice as a result of human cholesteryl ester transfer protein
transgene expression. Arterioscler. Thromb. Vasc. Biol. 19: 1105–1110.
136. Okamoto, H., F. Yonemori, K. Wakitani, T. Minowa, K. Maeda, and H. Shinkai.
2000. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis
in rabbits. Nature. 406: 203–207.
137. Sugano, M., N. Makino, S. Sawada, S. Otsuka, M. Watanabe, H. Okamoto, M.
Kamada, and A. Mizushima. 1998. Effect of Antisense Oligonucleotides
against Cholesteryl Ester Transfer Protein on the Development of
Atherosclerosis in Cholesterol-fed Rabbits. J. Biol. Chem. 273: 5033–5036.
138. Rittershaus, C. W., D. P. Miller, L. J. Thomas, M. D. Picard, C. M. Honan, C. D.
Emmett, C. L. Pettey, H. Adari, R. A. Hammond, D. T. Beattie, A. D.
Callow, H. C. Marsh, and U. S. Ryan. 2000. Vaccine-induced antibodies
inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of
atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20: 2106–2112.
139. Hayek, T., L. Masucci-Magoulas, X. Jiang, A. Walsh, E. Rubin, J. L. Breslow, and
A. R. Tall. 1995. Decreased early atherosclerotic lesions in
hypertriglyceridemic mice expressing cholesteryl ester transfer protein
transgene. J. Clin. Invest. 96: 2071–2074.
140. Föger, B., M. Chase, M. J. Amar, B. L. Vaisman, R. D. Shamburek, B. Paigen, J.
Fruchart-Najib, J. A. Paiz, C. A. Koch, R. F. Hoyt, H. B. Brewer, and S.
Santamarina-Fojo. 1999. Cholesteryl ester transfer protein corrects

131

dysfunctional high density lipoproteins and reduces aortic atherosclerosis in
lecithin cholesterol acyltransferase transgenic mice. J. Biol. Chem. 274:
36912–36920.
141. Vasan, R. S., M. J. Pencina, S. J. Robins, J. P. Zachariah, G. Kaur, R. B.
D’Agostino, and J. M. Ordovas. 2009. Association of circulating cholesteryl
ester transfer protein activity with incidence of cardiovascular disease in the
community. Circulation. 120: 2414–2420.
142. Khera, A. V., M. L. Wolfe, C. P. Cannon, J. Qin, and D. J. Rader. 2010. On-statin
cholesteryl ester transfer protein mass and risk of recurrent coronary events
(from the pravastatin or atorvastatin evaluation and infection therapythrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study). Am.
J. Cardiol. 106: 451–456.
143. Duwensee, K., L. P. Breitling, I. Tancevski, D. Rothenbacher, E. Demetz, J. R.
Patsch, A. Ritsch, P. Eller, and H. Brenner. 2010. Cholesteryl ester transfer
protein in patients with coronary heart disease. Eur. J. Clin. Invest. 40: 616–
622.
144. Ritsch, A., H. Scharnagl, P. Eller, I. Tancevski, K. Duwensee, E. Demetz, A.
Sandhofer, B. O. Boehm, B. R. Winkelmann, J. R. Patsch, and W. März.
2010. Cholesteryl ester transfer protein and mortality in patients undergoing
coronary angiography: the Ludwigshafen Risk and Cardiovascular Health
study. Circulation. 121: 366–374.

132

145. Robins, S. J., A. Lyass, R. W. Brocia, J. M. Massaro, and R. S. Vasan. 2013. Plasma
lipid transfer proteins and cardiovascular disease. The Framingham Heart
Study. Atherosclerosis. 228: 230–236.
146. Marschang, P., A. Sandhofer, A. Ritsch, I. Fiŝer, E. Kvas, and J. R. Patsch. 2006.
Plasma cholesteryl ester transfer protein concentrations predict
cardiovascular events in patients with coronary artery disease treated with
pravastatin. Journal of Internal Medicine. 260: 151–159.
147. Miller, N. E. 2015. Cholesteryl ester transfer protein: ace of spades, queen of hearts,
or the joker? Front Pharmacol. 6. [online]
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500898/ (Accessed March
14, 2016).
148. Miller, N. E. 2014. CETP inhibitors and cardiovascular disease: Time to think again.
F1000Research. [online] http://f1000research.com/articles/3-124/v1
(Accessed March 18, 2016).
149. Wojtaszewski, J. F. P., J. B. Birk, C. Frøsig, M. Holten, H. Pilegaard, and F. Dela.
2005. 5′AMP activated protein kinase expression in human skeletal muscle:
effects of strength training and type 2 diabetes. The Journal of Physiology.
564: 563–573.
150. Wu, J., D. Puppala, X. Feng, M. Monetti, A. L. Lapworth, and K. F. Geoghegan.
2013. Chemoproteomic Analysis of Intertissue and Interspecies Isoform

133

Diversity of AMP-activated Protein Kinase (AMPK). J Biol Chem. 288:
35904–35912.
151. Hardie, D. G. 2015. AMPK: positive and negative regulation, and its role in wholebody energy homeostasis. Current Opinion in Cell Biology. 33: 1–7.
152. Hardie, D. G. 2014. AMP-Activated Protein Kinase: Maintaining Energy
Homeostasis at the Cellular and Whole-Body Levels. Annual Review of
Nutrition. 34: 31–55.
153. Fullerton, M. D., G. R. Steinberg, and J. D. Schertzer. 2013. Immunometabolism of
AMPK in insulin resistance and atherosclerosis. Molecular and Cellular
Endocrinology. 366: 224–34.
154. Hawley, S. A., M. D. Fullerton, F. A. Ross, J. D. Schertzer, C. Chevtzoff, K. J.
Walker, M. W. Peggie, D. Zibrova, K. A. Green, K. J. Mustard, B. E. Kemp,
K. Sakamoto, G. R. Steinberg, and D. G. Hardie. 2012. The ancient drug
salicylate directly activates AMP-activated protein kinase. Science. 336:
918–22.
155. Steinberg, G. R., M. Dandapani, and D. G. Hardie. 2013. AMPK: mediating the
metabolic effects of salicylate-based drugs? Trends in Endocrinology &
Metabolism. 24: 481–7.
156. Ford, R. J., M. D. Fullerton, S. L. Pinkosky, E. A. Day, J. W. Scott, J. S. Oakhill, A.
L. Bujak, B. K. Smith, J. D. Crane, R. M. Blümer, K. Marcinko, B. E.
Kemp, H. C. Gerstein, and G. R. Steinberg. 2015. Metformin and salicylate

134

synergistically activate liver AMPK, inhibit lipogenesis and improve insulin
sensitivity. Biochem. J. 468: 125–132.
157. Cao, J., S. Meng, E. Chang, K. Beckwith-Fickas, L. Xiong, R. N. Cole, S. Radovick,
F. E. Wondisford, and L. He. 2014. Low concentrations of metformin
suppress glucose production in hepatocytes through AMP-activated protein
kinase (AMPK). J. Biol. Chem. 289: 20435–20446.
158. He, L., and F. E. Wondisford. 2015. Metformin Action: Concentrations Matter. Cell
Metabolism. 21: 159–162.
159. Fullerton, M. D., S. Galic, K. Marcinko, S. Sikkema, T. Pulinilkunnil, Z.-P. Chen,
H. M. O’Neill, R. J. Ford, R. Palanivel, M. O’Brien, D. G. Hardie, S. L.
Macaulay, J. D. Schertzer, J. R. B. Dyck, B. J. van Denderen, B. E. Kemp,
and G. R. Steinberg. 2013. Single phosphorylation sites in Acc1 and Acc2
regulate lipid homeostasis and the insulin-sensitizing effects of metformin.
Nat. Med. 19: 1649–1654.
160. Foretz, M., and B. Viollet. 2015. Therapy: Metformin takes a new route to clinical
efficacy. Nat Rev Endocrinol.
161. Gillespie, J. G., and D. G. Hardie. 1992. Phosphorylation and inactivation of HMGCoA reductase at the AMP-activated protein kinase site in response to
fructose treatment of isolated rat hepatocytes. FEBS Lett. 306: 59–62.
162. Sim, A. T., and D. G. Hardie. 1988. The low activity of acetyl-CoA carboxylase in
basal and glucagon-stimulated hepatocytes is due to phosphorylation by the

135

AMP-activated protein kinase and not cyclic AMP-dependent protein kinase.
FEBS Lett. 233: 294–298.
163. Fullerton, M. D. 2016. AMP-activated protein kinase and its multifaceted regulation
of hepatic metabolism. Current Opinion in Lipidology. [online]
http://journals.lww.com/colipidology/Abstract/publishahead/AMP_activated_protein_kinase_and_its_
multifaceted.99578.aspx (Accessed March 2, 2016).
164. Srivastava, R. A. K., S. L. Pinkosky, S. Filippov, J. C. Hanselman, C. T. Cramer,
and R. S. Newton. 2012. AMP-activated protein kinase: an emerging drug
target to regulate imbalances in lipid and carbohydrate metabolism to treat
cardio-metabolic diseases. J. Lipid Res. 53: 2490–2514.
165. Wang, Q., L. Jiang, J. Wang, S. Li, Y. Yu, J. You, R. Zeng, X. Gao, L. Rui, W. Li,
and Y. Liu. 2009. Abrogation of hepatic ATP-citrate lyase protects against
fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice.
Hepatology. 49: 1166–1175.
166. Wang, Q., S. Li, L. Jiang, Y. Zhou, Z. Li, M. Shao, W. Li, and Y. Liu. 2010.
Deficiency in hepatic ATP-citrate lyase affects VLDL-triglyceride
mobilization and liver fatty acid composition in mice. J. Lipid Res. 51:
2516–2526.

136

167. Berwick, D. C., I. Hers, K. J. Heesom, S. K. Moule, and J. M. Tavaré. 2002. The
Identification of ATP-citrate Lyase as a Protein Kinase B (Akt) Substrate in
Primary Adipocytes. J. Biol. Chem. 277: 33895–33900.
168. Filippov, S., S. L. Pinkosky, and R. S. Newton. 2014. LDL-cholesterol reduction in
patients with hypercholesterolemia by modulation of adenosine
triphosphate-citrate lyase and adenosine monophosphate-activated protein
kinase. Curr. Opin. Lipidol. 25: 309–315.
169. Cramer, C. T., B. Goetz, K. L. M. Hopson, G. J. Fici, R. M. Ackermann, S. C.
Brown, C. L. Bisgaier, W. G. Rajeswaran, D. C. Oniciu, and M. E. Pape.
2004. Effects of a novel dual lipid synthesis inhibitor and its potential utility
in treating dyslipidemia and metabolic syndrome. J. Lipid Res. 45: 1289–
1301.
170. Lemus, H. N., and C. O. Mendivil. 2015. Adenosine triphosphate citrate lyase:
Emerging target in the treatment of dyslipidemia. Journal of Clinical
Lipidology. 9: 384–389.
171. Ballantyne, C. M., M. H. Davidson, D. E. Macdougall, H. E. Bays, L. A. Dicarlo, N.
L. Rosenberg, J. Margulies, and R. S. Newton. 2013. Efficacy and safety of
a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine
monophosphate-activated protein kinase in patients with
hypercholesterolemia: results of a multicenter, randomized, double-blind,
placebo-controlled, parallel-group trial. J. Am. Coll. Cardiol. 62: 1154–
1162.

137

172. Gutierrez, M. J., N. L. Rosenberg, D. E. Macdougall, J. C. Hanselman, J. R.
Margulies, P. Strange, M. A. Milad, S. J. McBride, and R. S. Newton. 2014.
Efficacy and safety of ETC-1002, a novel investigational low-density
lipoprotein-cholesterol-lowering therapy for the treatment of patients with
hypercholesterolemia and type 2 diabetes mellitus. Arterioscler. Thromb.
Vasc. Biol. 34: 676–683.
173. Thompson, P. D., J. Rubino, M. J. Janik, D. E. MacDougall, S. J. McBride, J. R.
Margulies, and R. S. Newton. 2015. Use of ETC-1002 to treat
hypercholesterolemia in patients with statin intolerance. Journal of Clinical
Lipidology. 9: 295–304.
174. Thompson, P. D., D. E. MacDougall, R. S. Newton, J. R. Margulies, J. C.
Hanselman, D. G. Orloff, J. M. McKenney, and C. M. Ballantyne. 2016.
Treatment with ETC-1002 alone and in combination with ezetimibe lowers
LDL cholesterol in hypercholesterolemic patients with or without statin
intolerance. Journal of Clinical Lipidology. 0. [online]
http://www.lipidjournal.com/article/S1933287415300702/abstract (Accessed
February 25, 2016).
175. Ballantyne, C. M., J. M. McKenney, D. E. MacDougall, J. R. Margulies, P. L.
Robinson, J. C. Hanselman, and N. D. Lalwani. 2016. Effect of ETC-1002
on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic
Patients Receiving Statin Therapy. The American Journal of Cardiology.
[online]

138

http://www.sciencedirect.com/science/article/pii/S0002914916304301
(Accessed April 14, 2016).
176. Bempedoic Acid | Esperion Therapeutics. [online]
http://www.esperion.com/therapies-progress/etc-1002/ (Accessed February
25, 2016).
177. Pinkosky, S. L., S. Filippov, R. A. K. Srivastava, J. C. Hanselman, C. D. Bradshaw,
T. R. Hurley, C. T. Cramer, M. A. Spahr, A. F. Brant, J. L. Houghton, C.
Baker, M. Naples, K. Adeli, and R. S. Newton. 2013. AMP-activated protein
kinase and ATP-citrate lyase are two distinct molecular targets for ETC1002, a novel small molecule regulator of lipid and carbohydrate
metabolism. J. Lipid Res. 54: 134–151.
178. Filippov, S., S. L. Pinkosky, R. J. Lister, C. Pawloski, J. C. Hanselman, C. T.
Cramer, R. A. K. Srivastava, T. R. Hurley, C. D. Bradshaw, M. A. Spahr,
and R. S. Newton. 2013. ETC-1002 regulates immune response, leukocyte
homing, and adipose tissue inflammation via LKB1-dependent activation of
macrophage AMPK. J. Lipid Res. 54: 2095–2108.
179. Nikolic, D., D. P. Mikhailidis, M. H. Davidson, M. Rizzo, and M. Banach. 2014.
ETC-1002: A future option for lipid disorders? Atherosclerosis. 237: 705–
710.
180. Pinkosky, S. L., R. S. Newton, C. M. Birch, S. Filippov, P. H. Groot, and N. D.
Lalwani. 2015. Abstract 17608: Identification of a Tissue-specific Very

139

Long-chain Acyl-CoA Synthetase Involved in the Inhibition of ATP-Citrate
Lyase (ACL) by ETC-1002: A Novel Mechanism for Cholesterol
Biosynthesis Inhibition in the Liver. Circulation. 132: A17608–A17608.
181. Cramer, C. T., R. A. Srivastava, J. Lutostanski, C. L. Bisgaier, and R. S. Newton.
2011. In ATVB Scientific Sessions. pp. 28–30. , Chicago, IL.
182. Collins, S. Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse:
physiological and molecular characteristics. Physiology and Behavior. 81:
243–248.
183. Alexander, J., G. Q. Chang, J. T. Dourmashkin, and S. F. Leibowitz. 2006. Distinct
phenotypes of obesity-prone AKR/J, DBA2J and C57BL/6J mice compared
to control strains. Int J Obes (Lond). 30: 50–59.
184. Whitman, S. C. 2004. A Practical Approach to Using Mice in Atherosclerosis
Research. Clin Biochem Rev. 25: 81–93.
185. Getz, G., and C. Reardon. 2015. In Methods in Mouse Atherosclerosis Methods in
Molecular Biology (Andrés, V., and Dorado, B., eds.). pp. 1–16. , Springer
New York. [online] http://dx.doi.org/10.1007/978-1-4939-2929-0_1
(Accessed February 26, 2016).
186. Subramanian, S., C. Y. Han, T. Chiba, T. S. McMillen, S. A. Wang, A. Haw, E. A.
Kirk, K. D. O’Brien, and A. Chait. 2008. Dietary cholesterol worsens
adipose tissue macrophage accumulation and atherosclerosis in obese LDL
receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 28: 685–691.

140

187. Subramanian, S., L. Goodspeed, S. Wang, J. Kim, L. Zeng, G. N. Ioannou, W. G.
Haigh, M. M. Yeh, K. V. Kowdley, K. D. O’Brien, S. Pennathur, and A.
Chait. 2011. Dietary cholesterol exacerbates hepatic steatosis and
inflammation in obese LDL receptor-deficient mice. J. Lipid Res. 52: 1626–
1635.
188. Bieghs, V., P. J. Van Gorp, K. Wouters, T. Hendrikx, M. J. Gijbels, M. van Bilsen,
J. Bakker, C. J. Binder, D. Lütjohann, B. Staels, M. H. Hofker, and R. ShiriSverdlov. 2012. LDL Receptor Knock-Out Mice Are a Physiological Model
Particularly Vulnerable to Study the Onset of Inflammation in NonAlcoholic Fatty Liver Disease. PLoS One. 7. [online]
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266276/ (Accessed April 1,
2016).
189. Joven, J., A. Rull, N. Ferré, J. C. Escolà-Gil, J. Marsillach, B. Coll, C. AlonsoVillaverde, G. Aragones, J. Claria, and J. Camps. 2007. The results in rodent
models of atherosclerosis are not interchangeable: The influence of diet and
strain. Atherosclerosis. 195: e85–e92.
190. Davies, S. P., D. Carling, M. R. Munday, and D. G. Hardie. 1992. Diurnal rhythm of
phosphorylation of rat liver acetyl-CoA carboxylase by the AMP-activated
protein kinase, demonstrated using freeze-clamping. Effects of high fat diets.
Eur. J. Biochem. 203: 615–623.
191. Mulvihill, E. E., E. M. Allister, B. G. Sutherland, D. E. Telford, C. G. Sawyez, J. Y.
Edwards, J. M. Markle, R. A. Hegele, and M. W. Huff. 2009. Naringenin

141

prevents dyslipidemia, apolipoprotein B overproduction, and
hyperinsulinemia in LDL receptor-null mice with diet-induced insulin
resistance. Diabetes. 58: 2198–2210.
192. Granton, P. V., C. J. D. Norley, J. Umoh, E. A. Turley, B. C. Frier, E. G. Noble, and
D. W. Holdsworth. 2010. Rapid in vivo whole body composition of rats
using cone beam μCT. J. Appl. Physiol. 109: 1162–1169.
193. Assini, J. M., E. E. Mulvihill, A. C. Burke, B. G. Sutherland, D. E. Telford, S. S.
Chhoker, C. G. Sawyez, M. Drangova, A. C. Adams, A. Kharitonenkov, C.
L. Pin, and M. W. Huff. 2015. Naringenin prevents obesity, hepatic
steatosis, and glucose intolerance in male mice independent of fibroblast
growth factor 21. Endocrinology. 156: 2087–2102.
194. Assini, J. M., E. E. Mulvihill, B. G. Sutherland, D. E. Telford, C. G. Sawyez, S. L.
Felder, S. Chhoker, J. Y. Edwards, R. Gros, and M. W. Huff. 2013.
Naringenin prevents cholesterol-induced systemic inflammation, metabolic
dysregulation, and atherosclerosis in Ldlr−/− mice. J. Lipid Res. 54: 711–724.
195. Bojic, L. A., A. C. Burke, S. S. Chhoker, D. E. Telford, B. G. Sutherland, J. Y.
Edwards, C. G. Sawyez, R. G. Tirona, H. Yin, J. G. Pickering, and M. W.
Huff. 2014. Peroxisome proliferator-activated receptor δ agonist GW1516
attenuates diet-induced aortic inflammation, insulin resistance, and
atherosclerosis in low-density lipoprotein receptor knockout mice.
Arterioscler. Thromb. Vasc. Biol. 34: 52–60.

142

196. Hadi, A. M., K. T. B. Mouchaers, I. Schalij, K. Grunberg, G. A. Meijer, A. VonkNoordegraaf, W. J. van der Laarse, and J. A. M. Beliën. 2011. Rapid
quantification of myocardial fibrosis: a new macro-based automated
analysis. Cell Oncol (Dordr). 34: 343–354.
197. Ruifrok, A. C., and D. A. Johnston. 2001. Quantification of histochemical staining
by color deconvolution. Anal. Quant. Cytol. Histol. 23: 291–299.
198. Landini, G. 2009. Colour Deconvolution using ImageJ. [online]
http://www.mecourse.com/landinig/software/cdeconv/cdeconv.html
(Accessed April 28, 2016).
199. Folch, J., M. Lees, and G. H. S. Stanley. 1957. A Simple Method for the Isolation
and Purification of Total Lipides from Animal Tissues. J. Biol. Chem. 226:
497–509.
200. Mulvihill, E. E., J. M. Assini, J. K. Lee, E. M. Allister, B. G. Sutherland, J. B.
Koppes, C. G. Sawyez, J. Y. Edwards, D. E. Telford, A. Charbonneau, P. StPierre, A. Marette, and M. W. Huff. 2011. Nobiletin attenuates VLDL
overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced
insulin resistance. Diabetes. 60: 1446–57.
201. King, V. L., J. Thompson, and L. R. Tannock. 2011. Serum amyloid A in
atherosclerosis. Curr. Opin. Lipidol. 22: 302–307.

143

202. Krishack, P. A., C. V. Bhanvadia, J. Lukens, T. J. Sontag, M. C. De Beer, G. S.
Getz, and C. A. Reardon. 2015. Serum Amyloid A Facilitates Early Lesion
Development in Ldlr-/- Mice. J Am Heart Assoc. 4.
203. Stroes, E. S., P. D. Thompson, A. Corsini, G. D. Vladutiu, F. J. Raal, K. K. Ray, M.
Roden, E. Stein, L. Tokgözoğlu, B. G. Nordestgaard, E. Bruckert, G. De
Backer, R. M. Krauss, U. Laufs, R. D. Santos, R. A. Hegele, G. K. Hovingh,
L. A. Leiter, F. Mach, W. März, C. B. Newman, O. Wiklund, T. A.
Jacobson, A. L. Catapano, M. J. Chapman, H. N. Ginsberg, and European
Atherosclerosis Society Consensus Panel. 2015. Statin-associated muscle
symptoms: impact on statin therapy-European Atherosclerosis Society
Consensus Panel Statement on Assessment, Aetiology and Management.
Eur. Heart J.
204. Banach, M., M. Rizzo, P. P. Toth, M. Farnier, M. H. Davidson, K. Al-Rasadi, W. S.
Aronow, V. Athyros, D. M. Djuric, M. V. Ezhov, R. S. Greenfield, G. K.
Hovingh, K. Kostner, C. Serban, D. Lighezan, Z. Fras, P. M. Moriarty, P.
Muntner, A. Goudev, R. Ceska, S. J. Nicholls, M. Broncel, D. Nikolic, D.
Pella, R. Puri, J. Rysz, N. D. Wong, L. Bajnok, S. R. Jones, K. K. Ray, and
D. P. Mikhailidis. 2015. Statin intolerance – an attempt at a unified
definition. Position paper from an International Lipid Expert Panel. Arch
Med Sci. 11: 1–23.
205. Fitchett, D. H., R. A. Hegele, and S. Verma. 2015. Statin Intolerance. Circulation.
131: e389–e391.

144

206. Mancini, G. B. J., S. Baker, J. Bergeron, D. Fitchett, J. Frohlich, J. Genest, M.
Gupta, R. A. Hegele, D. Ng, G. J. Pearson, J. Pope, and A. Y. Tashakkor.
Diagnosis, Prevention and Management of Statin Adverse Effects and
Intolerance: Canadian Consensus Working Group Update (2016). Canadian
Journal of Cardiology. [online]
http://www.sciencedirect.com/science/article/pii/S0828282X16000076
(Accessed April 19, 2016).
207. Spence, J. D., and G. K. Dresser. 2016. Overcoming Challenges With Statin
Therapy. J Am Heart Assoc. 5: e002497.
208. Laufs, U., H. Scharnagl, and W. März. 2015. Statin intolerance: Current Opinion in
Lipidology. 26: 492–501.
209. Wei, W., A. G. Schwaid, X. Wang, X. Wang, S. Chen, Q. Chu, A. Saghatelian, and
Y. Wan. 2016. Ligand Activation of ERRα by Cholesterol Mediates Statin
and Bisphosphonate Effects. Cell Metabolism. 23: 479–491.
210. Schirris, T. J. J., G. H. Renkema, T. Ritschel, N. C. Voermans, A. Bilos, B. G. M.
van Engelen, U. Brandt, W. J. H. Koopman, J. D. Beyrath, R. J. Rodenburg,
P. H. G. M. Willems, J. A. M. Smeitink, and F. G. M. Russel. 2015. StatinInduced Myopathy Is Associated with Mitochondrial Complex III Inhibition.
Cell Metabolism. 22: 399–407.
211. Ayala, J. E., V. T. Samuel, G. J. Morton, S. Obici, C. M. Croniger, G. I. Shulman,
D. H. Wasserman, and O. P. McGuinness. 2010. Standard operating

145

procedures for describing and performing metabolic tests of glucose
homeostasis in mice. Dis Model Mech. 3: 525–534.
212. McGuinness, O. P., J. E. Ayala, M. R. Laughlin, and D. H. Wasserman. 2009. NIH
experiment in centralized mouse phenotyping: the Vanderbilt experience and
recommendations for evaluating glucose homeostasis in the mouse.
American Journal of Physiology - Endocrinology and Metabolism. 297:
E849–E855.
213. Andrikopoulos, S., A. R. Blair, N. Deluca, B. C. Fam, and J. Proietto. 2008.
Evaluating the glucose tolerance test in mice. American Journal of
Physiology - Endocrinology and Metabolism. 295: E1323–E1332.
214. King, A. J. 2012. The use of animal models in diabetes research. British Journal of
Pharmacology. 166: 877–894.
215. Bowe, J. E., Z. J. Franklin, A. C. Hauge-Evans, A. J. King, S. J. Persaud, and P. M.
Jones. 2014. METABOLIC PHENOTYPING GUIDELINES: Assessing
glucose homeostasis in rodent models. J Endocrinol. 222: G13–G25.
216. Kondrup, J., and P. B. Lazarow. 1985. Flux of palmitate through the peroxisomal
and mitochondrial beta-oxidation systems in isolated rat hepatocytes.
Biochim. Biophys. Acta. 835: 147–153.
217. Camões, F., N. A. Bonekamp, H. K. Delille, and M. Schrader. 2009. Organelle
dynamics and dysfunction: A closer link between peroxisomes and
mitochondria. J. Inherit. Metab. Dis. 32: 163–180.

146

218. Thoms, S., S. Grønborg, and J. Gärtner. 2009. Organelle interplay in peroxisomal
disorders. Trends in Molecular Medicine. 15: 293–302.
219. Yotsumoto, T., T. Naitoh, M. Kitahara, and N. Tsuruzoe. 2000. Effects of carnitine
palmitoyltransferase I inhibitors on hepatic hypertrophy. European Journal
of Pharmacology. 398: 297–302.
220. Previs, S. F., D. G. McLaren, S.-P. Wang, S. J. Stout, H. Zhou, K. Herath, V. Shah,
P. L. Miller, L. Wilsie, J. Castro-Perez, D. G. Johns, M. A. Cleary, and T. P.
Roddy. 2014. New methodologies for studying lipid synthesis and turnover:
Looking backwards to enable moving forwards. Biochimica et Biophysica
Acta (BBA) - Molecular Basis of Disease. 1842: 402–413.
221. Dietschy, J. M., and J. D. McGarry. 1974. Limitations of Acetate as a Substrate for
Measuring Cholesterol Synthesis in Liver. J. Biol. Chem. 249: 52–58.
222. Gandemer, G., G. Pascal, and G. Durand. 1983. Lipogenic capacity and relative
contribution of the different tissues and organs to lipid synthesis in male rat.
Reprod Nutr Dev. 23: 575–586.
223. Dietschy, J. M., and M. S. Brown. 1974. Effect of alterations of the specific activity
of the intracellular acetyl CoA pool on apparent rates of hepatic
cholesterogenesis. J. Lipid Res. 15: 508–516.
224. Serdarevich, B., and K. K. Carroll. 1972. In Vivo Incorporation of Labeled Acetate
into Liver and Serum Lipids of Rate on Different Dietary Regimens. Can. J.
Biochem. 50: 557–562.

147

225. Tschöp, M. H., J. R. Speakman, J. R. S. Arch, J. Auwerx, J. C. Brüning, L. Chan, R.
H. Eckel, R. V. Farese Jr, J. E. Galgani, C. Hambly, M. A. Herman, T. L.
Horvath, B. B. Kahn, S. C. Kozma, E. Maratos-Flier, T. D. Müller, H.
Münzberg, P. T. Pfluger, L. Plum, M. L. Reitman, K. Rahmouni, G. I.
Shulman, G. Thomas, C. R. Kahn, and E. Ravussin. 2012. A guide to
analysis of mouse energy metabolism. Nat Meth. 9: 57–63.
226. Speakman, J. R. 2013. Measuring energy metabolism in the mouse - theoretical,
practical, and analytical considerations. Front Physiol. 4: 34.
227. van Klinken, J. B., S. A. A. van den Berg, and K. W. van Dijk. 2013. Practical
aspects of estimating energy components in rodents. Front Physiol. 4: 94.
228. Burnett, C. M. L., and J. L. Grobe. 2014. Dietary effects on resting metabolic rate in
C57BL/6 mice are differentially detected by indirect (O2/CO2 respirometry)
and direct calorimetry. Molecular Metabolism. 3: 460–464.
229. Speakman, J. R. 2014. Should we abandon indirect calorimetry as a tool to diagnose
energy expenditure? Not yet. Perhaps not ever. Commentary on Burnett and
Grobe (2014). Molecular Metabolism. 3: 342–344.
230. Kaiyala, K. J. 2014. What does indirect calorimetry really tell us? Molecular
Metabolism. 3: 340–341.
231. Butler, A. A., and L. P. Kozak. 2010. A Recurring Problem With the Analysis of
Energy Expenditure in Genetic Models Expressing Lean and Obese
Phenotypes. Diabetes. 59: 323–329.

148

232. Huang, H., T. Liu, J. L. Rose, R. L. Stevens, and D. G. Hoyt. 2007. Sensitivity of
mice to lipopolysaccharide is increased by a high saturated fat and
cholesterol diet. Journal of Inflammation. 4: 22.
233. Zhao, L., S. Zhong, H. Qu, Y. Xie, Z. Cao, Q. Li, P. Yang, Z. Varghese, J. F.
Moorhead, Y. Chen, and X. Z. Ruan. 2015. Chronic inflammation
aggravates metabolic disorders of hepatic fatty acids in high-fat diet-induced
obese mice. Scientific Reports. 5: 10222.
234. Hirschfield, G. M., J. R. Gallimore, M. C. Kahan, W. L. Hutchinson, C. A. Sabin, G.
M. Benson, A. P. Dhillon, G. A. Tennent, and M. B. Pepys. 2005.
Transgenic human C-reactive protein is not proatherogenic in apolipoprotein
E-deficient mice. PNAS. 102: 8309–8314.
235. Cray, C., J. Zaias, and N. H. Altman. 2009. Acute Phase Response in Animals: A
Review. Comp Med. 59: 517–526.
236. Grahame Hardie, D. 2016. Regulation of AMP-activated protein kinase by natural
and synthetic activators. Acta Pharm Sin B. 6: 1–19.
237. Bitterman, J. L., and J. H. Chung. 2015. Metabolic effects of resveratrol: addressing
the controversies. Cell. Mol. Life Sci. 72: 1473–1488.
238. Zordoky, B. N. M., I. M. Robertson, and J. R. B. Dyck. 2015. Preclinical and
clinical evidence for the role of resveratrol in the treatment of cardiovascular
diseases. Biochim. Biophys. Acta. 1852: 1155–1177.

149

239. Szkudelski, T., and K. Szkudelska. 2015. Resveratrol and diabetes: from animal to
human studies. Biochim. Biophys. Acta. 1852: 1145–1154.
240. Zang, M., S. Xu, K. A. Maitland-Toolan, A. Zuccollo, X. Hou, B. Jiang, M.
Wierzbicki, T. J. Verbeuren, and R. A. Cohen. 2006. Polyphenols stimulate
AMP-activated protein kinase, lower lipids, and inhibit accelerated
atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes. 55: 2180–
2191.
241. Loke, W. M., J. M. Proudfoot, J. M. Hodgson, A. J. McKinley, N. Hime, M. Magat,
R. Stocker, and K. D. Croft. 2010. Specific Dietary Polyphenols Attenuate
Atherosclerosis in Apolipoprotein E–Knockout Mice by Alleviating
Inflammation and Endothelial Dysfunction. Arterioscler Thromb Vasc Biol.
30: 749–757.
242. Li, Y., S. Xu, M. M. Mihaylova, B. Zheng, X. Hou, B. Jiang, O. Park, Z. Luo, E.
Lefai, J. Y.-J. Shyy, B. Gao, M. Wierzbicki, T. J. Verbeuren, R. J. Shaw, R.
A. Cohen, and M. Zang. 2011. AMPK phosphorylates and inhibits SREBP
activity to attenuate hepatic steatosis and atherosclerosis in diet-induced
insulin-resistant mice. Cell Metab. 13: 376–388.
243. Cool, B., B. Zinker, W. Chiou, L. Kifle, N. Cao, M. Perham, R. Dickinson, A.
Adler, G. Gagne, R. Iyengar, G. Zhao, K. Marsh, P. Kym, P. Jung, H. S.
Camp, and E. Frevert. 2006. Identification and characterization of a small
molecule AMPK activator that treats key components of type 2 diabetes and
the metabolic syndrome. Cell Metabolism. 3: 403–416.

150

244. Göransson, O., A. McBride, S. A. Hawley, F. A. Ross, N. Shpiro, M. Foretz, B.
Viollet, D. G. Hardie, and K. Sakamoto. 2007. Mechanism of action of A769662, a valuable tool for activation of AMP-activated protein kinase. J.
Biol. Chem. 282: 32549–32560.
245. Sanders, M. J., Z. S. Ali, B. D. Hegarty, R. Heath, M. A. Snowden, and D. Carling.
2007. Defining the Mechanism of Activation of AMP-activated Protein
Kinase by the Small Molecule A-769662, a Member of the Thienopyridone
Family. J. Biol. Chem. 282: 32539–32548.
246. Scott, J. W., B. J. W. van Denderen, S. B. Jorgensen, J. E. Honeyman, G. R.
Steinberg, J. S. Oakhill, T. J. Iseli, A. Koay, P. R. Gooley, D. Stapleton, and
B. E. Kemp. 2008. Thienopyridone drugs are selective activators of AMPactivated protein kinase beta1-containing complexes. Chem. Biol. 15: 1220–
1230.
247. Xiao, B., M. J. Sanders, D. Carmena, N. J. Bright, L. F. Haire, E. Underwood, B. R.
Patel, R. B. Heath, P. A. Walker, S. Hallen, F. Giordanetto, S. R. Martin, D.
Carling, and S. J. Gamblin. 2013. Structural basis of AMPK regulation by
small molecule activators. Nat Commun. 4: 3017.
248. Lai, Y.-C., S. Kviklyte, D. Vertommen, L. Lantier, M. Foretz, B. Viollet, S. Hallén,
and M. H. Rider. 2014. A small-molecule benzimidazole derivative that
potently activates AMPK to increase glucose transport in skeletal muscle:
comparison with effects of contraction and other AMPK activators.
Biochemical Journal. 460: 363–375.

151

249. Zadra, G., C. Photopoulos, S. Tyekucheva, P. Heidari, Q. P. Weng, G. Fedele, H.
Liu, N. Scaglia, C. Priolo, E. Sicinska, U. Mahmood, S. Signoretti, N.
Birnberg, and M. Loda. 2014. A novel direct activator of AMPK inhibits
prostate cancer growth by blocking lipogenesis. EMBO Molecular Medicine.
6: 519–538.
250. Gómez-Galeno, J. E., Q. Dang, T. H. Nguyen, S. H. Boyer, M. P. Grote, Z. Sun, M.
Chen, W. A. Craigo, P. D. van Poelje, D. A. MacKenna, E. E. Cable, P. A.
Rolzin, P. D. Finn, B. Chi, D. L. Linemeyer, S. J. Hecker, and M. D. Erion.
2010. A Potent and Selective AMPK Activator That Inhibits de Novo
Lipogenesis. ACS Med. Chem. Lett. 1: 478–482.
251. Hunter, R. W., M. Foretz, L. Bultot, M. D. Fullerton, M. Deak, F. A. Ross, S. A.
Hawley, N. Shpiro, B. Viollet, D. Barron, B. E. Kemp, G. R. Steinberg, D.
G. Hardie, and K. Sakamoto. 2014. Mechanism of action of compound-13:
an α1-selective small molecule activator of AMPK. Chem. Biol. 21: 866–
879.
252. Anil, T. M., C. Harish, M. N. Lakshmi, K. Harsha, M. Onkaramurthy, V. Sathish
Kumar, N. Shree, V. Geetha, G. V. Balamurali, A. S. Gopala, B.
Madhusudhan Reddy, M. K. Govind, M. O. Anup, Y. Moolemath, M. V.
Venkataranganna, M. R. Jagannath, and B. P. Somesh. 2014. CNX-012-570,
a direct AMPK activator provides strong glycemic and lipid control along
with significant reduction in body weight; studies from both diet-induced
obese mice and db/db mice models. Cardiovascular Diabetology. 13: 27.

152

253. Chypre, M., N. Zaidi, and K. Smans. 2012. ATP-citrate lyase: a mini-review.
Biochem. Biophys. Res. Commun. 422: 1–4.
254. Lowenstein, J. M. 1971. Effect of (—)-Hydroxycitrate on Fatty Acid Synthesis by
Rat Liver in Vivo. J. Biol. Chem. 246: 629–632.
255. Barth, C., J. Hackenschmidt, H. Ullmann, and K. Decker. 1972. Inhibition of
cholesterol synthesis by (−)-hydroxycitrate in perfused rat liver. Evidence
for an extramitochondrial mevalonate synthesis from acetyl coenzyme A.
FEBS Letters. 22: 343–346.
256. Sullivan, A. C., J. Triscari, J. G. Hamilton, and J. A. Ontko. 1977. Hypolipidemic
activity of (−)-hydroxycitrate. Lipids. 12: 1–9.
257. Madeo, F., F. Pietrocola, T. Eisenberg, and G. Kroemer. 2014. Caloric restriction
mimetics: towards a molecular definition. Nat Rev Drug Discov. 13: 727–
740.
258. Ma, Z., C.-H. Chu, and D. Cheng. 2009. A novel direct homogeneous assay for ATP
citrate lyase. J. Lipid Res. 50: 2131–2135.
259. Li, J. J., H. Wang, J. A. Tino, J. A. Robl, T. F. Herpin, R. M. Lawrence, S. Biller, H.
Jamil, R. Ponticiello, L. Chen, C. Chu, N. Flynn, D. Cheng, R. Zhao, B.
Chen, D. Schnur, M. T. Obermeier, V. Sasseville, R. Padmanabha, K. Pike,
and T. Harrity. 2007. 2-Hydroxy-N-arylbenzenesulfonamides as ATP-citrate
lyase inhibitors. Bioorganic & Medicinal Chemistry Letters. 17: 3208–3211.

153

260. Hatzivassiliou, G., F. Zhao, D. E. Bauer, C. Andreadis, A. N. Shaw, D. Dhanak, S.
R. Hingorani, D. A. Tuveson, and C. B. Thompson. 2005. ATP citrate lyase
inhibition can suppress tumor cell growth. Cancer Cell. 8: 311–321.
261. Chu, K. Y., Y. Lin, A. Hendel, J. E. Kulpa, R. W. Brownsey, and J. D. Johnson.
2010. ATP-Citrate Lyase Reduction Mediates Palmitate-induced Apoptosis
in Pancreatic Beta Cells. J. Biol. Chem. 285: 32606–32615.
262. Pearce, N. J., J. W. Yates, T. A. Berkhout, B. Jackson, D. Tew, H. Boyd, P.
Camilleri, P. Sweeney, A. D. Gribble, A. Shaw, and P. H. E. Groot. 1998.
The role of ATP citrate-lyase in the metabolic regulation of plasma lipids.
Biochemical Journal. 334: 113–119.
263. Abramson, H. N. 2011. The lipogenesis pathway as a cancer target. J. Med. Chem.
54: 5615–5638.
264. Sullivan, A. C., J. G. Hamilton, O. N. Miller, and V. R. Wheatley. 1972. Inhibition
of lipogenesis in rat liver by (−)-hydroxycitrate. Archives of Biochemistry
and Biophysics. 150: 183–190.
265. Duval, C., M. Müller, and S. Kersten. 2007. PPARα and dyslipidemia. Biochimica et
Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1771: 961–
971.
266. Hegele, R. A., H. N. Ginsberg, M. J. Chapman, B. G. Nordestgaard, J. A.
Kuivenhoven, M. Averna, J. Borén, E. Bruckert, A. L. Catapano, O. S.
Descamps, G. K. Hovingh, S. E. Humphries, P. T. Kovanen, L. Masana, P.

154

Pajukanta, K. G. Parhofer, F. J. Raal, K. K. Ray, R. D. Santos, A. F. H.
Stalenhoef, E. Stroes, M.-R. Taskinen, A. Tybjærg-Hansen, G. F. Watts, and
O. Wiklund. 2014. The polygenic nature of hypertriglyceridaemia:
implications for definition, diagnosis, and management. The Lancet Diabetes
& Endocrinology. 2: 655–666.
267. Zandbergen, F., and J. Plutzky. 2007. PPARα in atherosclerosis and inflammation.
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of
Lipids. 1771: 972–982.
268. Marx, N., H. Duez, J.-C. Fruchart, and B. Staels. 2004. Peroxisome ProliferatorActivated Receptors and Atherogenesis Regulators of Gene Expression in
Vascular Cells. Circ Res. 94: 1168–1178.
269. Kersten, S. 2014. Integrated physiology and systems biology of PPARα. Molecular
Metabolism. 3: 354–371.
270. Fu, T., P. Kashireddy, and J. Borensztajn. 2003. The peroxisome-proliferatoractivated receptor alpha agonist ciprofibrate severely aggravates
hypercholesterolaemia and accelerates the development of atherosclerosis in
mice lacking apolipoprotein E. Biochemical Journal. 373: 941–947.
271. Fu, T., D. Mukhopadhyay, N. O. Davidson, and J. Borensztajn. 2004. The
peroxisome proliferator-activated receptor alpha (PPARalpha) agonist
ciprofibrate inhibits apolipoprotein B mRNA editing in low density

155

lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the
development of atherosclerotic lesions. J. Biol. Chem. 279: 28662–28669.
272. Declercq, V., B. Yeganeh, G.-R. Moshtaghi-Kashanian, H. Khademi, B. Bahadori,
and M. H. Moghadasian. 2005. Paradoxical effects of fenofibrate and
nicotinic acid in apo E-deficient mice. J. Cardiovasc. Pharmacol. 46: 18–24.
273. Yeganeh, B., G.-R. Moshtaghi-Kashanian, V. Declercq, and M. H. Moghadasian.
2005. Combination of dietary phytosterols plus niacin or fenofibrate: effects
on lipid profile and atherosclerosis in apo E-KO mice. J. Nutr. Biochem. 16:
222–228.
274. Srivastava, R. A. K., R. Jahagirdar, S. Azhar, S. Sharma, and C. L. Bisgaier. 2006.
Peroxisome proliferator-activated receptor-α selective ligand reduces
adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL
receptor-deficient mice. Mol Cell Biochem. 285: 35–50.
275. Calkin, A. C., M. E. Cooper, K. A. Jandeleit-Dahm, and T. J. Allen. 2006.
Gemfibrozil decreases atherosclerosis in experimental diabetes in
association with a reduction in oxidative stress and inflammation.
Diabetologia. 49: 766–774.
276. Calkin, A. C., T. J. Allen, M. Lassila, C. Tikellis, K. A. Jandeleit-Dahm, and M. C.
Thomas. 2007. Increased atherosclerosis following treatment with a dual
PPAR agonist in the ApoE knockout mouse. Atherosclerosis. 195: 17–22.

156

277. Inaba, T., H. Yagyu, N. Itabashi, F. Tazoe, N. Fujita, S. Nagashima, K. Okada, M.
Okazaki, Y. Furukawa, and S. Ishibashi. 2008. Cholesterol Reduction and
Atherosclerosis Inhibition by Bezafibrate in Low-Density Lipoprotein
Receptor Knockout Mice. Hypertens Res. 31: 999–1005.
278. Marsman, D. S., T. L. Goldsworthy, and J. A. Popp. 1992. Contrasting hepatocytic
peroxisome proliferation, lipofuscin accumulation and cell turnover for the
hepatocarcinogens Wy-14,643 and clofibric acid. Carcinogenesis. 13: 1011–
1017.
279. Peters, J. M., C. Cheung, and F. J. Gonzalez. 2005. Peroxisome proliferatoractivated receptor-alpha and liver cancer: where do we stand? J. Mol. Med.
83: 774–785.
280. Rubenstrunk, A., R. Hanf, D. W. Hum, J.-C. Fruchart, and B. Staels. 2007. Safety
issues and prospects for future generations of PPAR modulators. Biochimica
et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1771:
1065–1081.
281. Holden, P. R., and J. D. Tugwood. 1999. Peroxisome proliferator-activated receptor
alpha: role in rodent liver cancer and species differences. J. Mol. Endocrinol.
22: 1–8.
282. Esperion Therapeutics Announces Removal of PPAR Partial Clinical Hold for ETC1002. 2015. [online]

157

http://investor.esperion.com/releasedetail.cfm?ReleaseID=894164 (Accessed
May 9, 2016).
283. Esperion Therapeutics, Inc. - Quarterly Report. 2015. [online]
http://investor.esperion.com/secfiling.cfm?filingID=1104659-15-76267
(Accessed May 9, 2016).
284. Chakravarthy, M. V., Z. Pan, Y. Zhu, K. Tordjman, J. G. Schneider, T. Coleman, J.
Turk, and C. F. Semenkovich. 2005. “New” hepatic fat activates PPARα to
maintain glucose, lipid, and cholesterol homeostasis. Cell Metabolism. 1:
309–322.
285. Chakravarthy, M. V., I. J. Lodhi, L. Yin, R. R. V. Malapaka, H. E. Xu, J. Turk, and
C. F. Semenkovich. 2009. Identification of a Physiologically Relevant
Endogenous Ligand for PPARα in Liver. Cell. 138: 476–488.
286. Jensen-Urstad, A. P. L., and C. F. Semenkovich. 2012. Fatty acid synthase and liver
triglyceride metabolism: Housekeeper or messenger? Biochimica et
Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1821: 747–
753.
287. Neschen, S., I. Moore, W. Regittnig, C. L. Yu, Y. Wang, M. Pypaert, K. F. Petersen,
and G. I. Shulman. 2002. Contrasting effects of fish oil and safflower oil on
hepatic peroxisomal and tissue lipid content. Am J Physiol Endocrinol
Metab. 282: E395–E401.

158

Curriculum Vitae
Name:

Joshua Peter Samsoondar

Post-secondary
Education and
Degrees:

The University of Western Ontario
London, Ontario, Canada
2009-2013 BMSc

Honours and
Awards:

CIHR Strategic Training Fellowship in Vascular Biology
Canadian Institutes of Health Research
2013-2015
Western Graduate Research Scholarship
2013-2015

Publications:
Dekker MJ, Baker C, Naples M, Samsoondar J, Zhang R, Qiu W, Sacco J, Adeli K:
Inhibition of sphingolipid synthesis improves dyslipidemia in the diet-induced hamster
model of insulin resistance: evidence for the role of sphingosine and sphinganine in
hepatic VLDL-apoB100 overproduction. Atherosclerosis 2013; 228:98-109.

